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ABSTRACT
This study was designed to explore heat shock protein 70 (hsp70) ability to
generate effective CD8+ T cell responses against intracellular pathogens, particularly
HSV. Hsp70 has been shown to cross-present or cross-prime exogenous foreign antigen
into the MHC class I pathway of antigen presentation, which is dependent upon the
proteasome as well as the transported associated with antigen processing. In addition to
cross presentation, hsp70 has also been shown to have a variety of affects upon antigen
presenting (APC) cells via a specific interaction between receptors found on the APC and
hsp70. Interaction between this protein and APC causes induction of various pro
inflammatory cytokines such as IL-1 and TNF-a in addition hsp70/APC interaction
initiates the APC to undergo a pattern of changes leading to its maturation. In terms of
the immune response, hsp70 has been shown to play two roles, firstly the ability to cross
present or cross-prime antigen and secondly hsp70 seems to function as a potent
adjuvant. To begin this evaluation we used confocal microscopy and determined that in
fact hsp70 does interact with APC. Then due to the very high level of conservation
between hsp70 from broad phylogenetic origins we choose to determine if hsp70 from
many sources had similar adjuvant properties. Using an ELISA based approach it was
found that in fact hsp70 from plant, bacteria, and man all had similar abilities to induce
11-6, 11-12, and TNF-a from spleenocytes. In addition evidence generated by FACS found
that the various hsp70 also caused the maturation of APC as measured by CD40 and
B7. l. Hsp70 are know to be the most conserved at the N-terminal ATP binding domain.
iv

Therefore using trypsinization hsp70 was cleaved generating the ATP binding domain
that was tested for adjuvant properties. Using the ATP domain in an ELISA based
adjuvant tests revealed it did not have adjuvant properties. Finally, since many cognate
MHC class I peptides have low affinity for hsp70 a hybrid peptide that contained a region
with 20 fold increased affinity for hsp70 was produced and tested in many assays. Using
hsp70 bound with the hybrid peptide to immunize mice and comparing the immune
response to mice immunized with hsp70 bound to a class I epitope alone demonstrated
that using hybrid peptides was in fact a better approach. In vitro follow up studies on the
hybrid peptides surprisingly showed that hybrid peptides alone can gain access to the
class I pathway of antigen presentation via an interaction with hsp70 on the surface of
APC. This interaction was proteasome sensitive and inhibited by antibodies against
hsp70.
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Chapter 1

Introduction
Herpes Virus
HSV Morphology
Herpes Simplex Virus (HSV) is a rather large enveloped virus that contains a
genome made up of double strained DNA 150 kilobases (kB) in size. The genome encodes
around 80 proteins of which some are structural and others are non-structural. The lipid
envelope, which is host derived, contains several viral glycoproteins that setve both the
virus, by acting as mediators of viral entry into host cells, and the host due to glycoproteins
acting as the most probable antigens for both humoral and T cell mediated immunity.
Beneath the envelope is an amorphous, proteinatious structure called the tegument. The
tegument contains many interesting proteins including the virion host shutoff protein
(VHS), which acts to shutoff host protein synthesis and degrade messenger RNA (mRNA),
and aTIF, a protein that in combination with other cellular factors like Oct8 initiates viral
gene expression. There are many non-structural proteins found in the virus some of these
proteins are dispensable for normal growth while others are critical to the viral life cycle.
One of the most fascinating aspects of non-structural proteins is that many function to
assist the virus in evading the host immune response. For example, the regulatory protein,
ICP47, has been shown to inhibit processing of antigens in the MHC class I pathway. This
is one of many means the virus utilizes to avoid the immune response. Finally, beneath the
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tegument is the nucleocapsid. This structure is icosahedral in shape and contains the linear
double strained viral DNA.

HSV Life Cycle
During infection HSV binds to the extracellular matrix via specific interactions of
viral glycoproteins, like glycoprotein B (gB), to heparan sulfate, chondrotian sulfate
proteoglycans, or other unknown cellular molecules. After contact of two or more viral
glycoproteins with the cellular matrix fusion, of the viral and plasma membranes is
initiated by additional viral glycoproteins such as gD, gB, and gH/gL. Fusion complete the
virus is uncoated thus freeing tegument proteins and the nucleocapsid to move into the
cytoplasm. Now in the cytoplasm the nucleocapsid interacts with microtubules, via an
unknown mechanism, and is transported to the nucleus. Tegument proteins disperse
throughout the cell to organelles like ribosomes (VHS) and the nucleus (VP16) and
perform a variety of functions. Once the nucleocapsid reaches the nucleus it binds to
nuclear pores and releases viral DNA into the nucleus, where the DNA circularizes. Next,
VP 16 interacts with host transcriptional factors or components to stimulate transcription of
immediate-early viral genes by the host's own RNA polymerase II. These transcripts are
translated and imported back into the nucleus where they serve to initiate transcription of
early genes, whose function is primarily restricted to DNA replication. Finally, the late
genes, which are mostly structural proteins, are transcribed. Many of these proteins are
inserted into the rough Endoplasmic Reticulum (ER), where they are modified by
glycosylation, and subsequently transported to the Golgi apparatus for further refinement.
After maturation in the Golgi, viral glycoproteins are transported to the plasma membrane
2

to wait for assembly with the rest of the viral structures. After viral DNA is replicated it is
packaged with capsid proteins in the nucleus. After packaging the capsids containing DNA
together with tegument proteins bud from the nucleus into the ER, where the structure is
thought to acquire portions of its envelope. Next, the virus passes through the lumen of the
ER to the plasma membrane where it interacts with awaiting viral glycoproteins thus
inducing a new vi,rion to bud from the plasma membrane ready to initiate the infectious
process in a neighboring cell or neuron.

Herpes Infection and Vaccines
HSV Vaccines
HSV infection is a prevalent infection and disease causing agent that is currently
uncontrollable by vaccines (29). To date prophylactic and therapeutic vaccines have failed
in containing HSV infection proving the need for a new approach (12). The problem
confronted in developing an effective vaccine for HS V is that virus spread occurs during
primary and recurrent infections, therefore the vaccine must generate an immune response
that prevents a primary infection or for previously infected individuals a potent vaccine
must preclude or contain recurrent infection from the virus. A very large proportion of
individuals in the United States, other industrialized countries, and even third world
countries are at present infected with either Herpes Simplex I or II. If a microorganism's
success is measured by the amount of genetic material that is disseminated and maintained
in a host population then HSV is extraordinarily successful. The fact that so many people
3

harbor the virus points to the virus's seeming ability to evade the immune response and
belies our understanding of the ecology between the virus and man. Nevertheless infected
individuals do develop immunity to HSV as evidenced by the fact that over time recurrent
infections diminish as does their severity. Recurrent HSV disease results from reactivation
of latent virus in sensory neurons and transmission to peripheral sites. Understanding the
mechanisms that maintain HSV in a latent state in sensory neurons should provide new
alternatives to reducing susceptibility to recurrent herpetic disease.

HSV Infection and Latency
The viral life cycle is initiated by contact of an uninfected individual to an infected
one that is actively shedding virus, either via an active lesion or subclinical site. Once the
virus reaches a new host it can infect through the skin or mucous membranes, replicate,
and subsequently cause a primary infection. During primary infection lesions are generally
confined to mucosa! surfaces and neural tissue innervating the site of inoculation; however
on rare occasions particularly in immunocomprimised individuals the virus can
disseminate to the central nervous system where it can cause severe neurological
symptoms and encephalitis often leading to death. Immunocompetent individuals do
recover from primary infections, but the virus remains behind entering into a latent state
where reactivation can occur at any time, which is the hallmark of herpes virus infections.
Latent infections are defined as persistent infections where the viral genome is present in
either the sacral dorsal root or trigeminal ganglia (SRG, TG), but viral gene expression is
highly limited and no infectious virus is produced. Reactivation of latent infections can
result in either clinical or sub-clinical infections, but in either case infectious virus is shed.
4

Exactly what causes a latent infection to reactivate is probably related to environmental
(UV light) or emotional stress, however this topic is largely unsolved and very
controversial. Again, the occurrence, duration, and severity of lesions resulting from virus
reactivation are usually less severe than those observed during primary infection.
Seemingly each subsequent time the virus undergoes reactivation the pathology cause by
the infection is diminished, which points to an acquired immune response that involves the
recall of memory B and T cells (85). The previous point gives hope to those desperately
attempting to develop a prophylactic or therapeutic vaccine, however in order to co-opt the
mechanisms that curtail pathology of recurrent infections we must first understand them.
At this point our understanding of the strategies employed by the immune system is
expanding, but still lacking.

HSV and CDS+ T Cell Immunobiology
CDS+ T cells and HSV Clearance
Much recent work has indicated that cellular immune mechanisms, particularly
CD8+ cytotoxic T lymphocytes (CTL), are crucial in containing HSV infection (17, 56).
Koelle's work clearly demonstrated that while natural killer cells (NK) and CD4+ cells are
present during host clearance of symptomatic HSY infection, CD8+ T cell appearance
coincides with resolution of lesions. This paper studied the functional properties of bulk
cultures of skin-infiltrating lymphocytes from normal skin and serial biopsies of recurrent
genital HSY-2 lesions, and compared HSY-specific T cell and NK responses with viral
5

clearance. RSV-specific CD4+ proliferative responses and NK-like cytotoxic responses
were present at all stages of infection, including biopsies early in the disease course. In
contrast, CDS+ cytotoxic activity was generally low among cells derived from early time
points, and increased during lesion evolution. Viral clearance was associated with a high
level of local cytolytic activity towards HSV infected cells by CD8+ T cells.

CDS+ T cells Protect Neurons from HSV
Other work demonstrates the importance of CDS+ T cells after primary herpes
simplex virus type 1 (HSV-1) corneal infection of mice (72). This work shows CD8+ T
cells infiltrate the TG of mice, and are retained in latently infected ganglia. The paper
demonstrates that CD8+ T cells that are present in the TG at the time of excision can
maintain HSV-1 in a latent state in sensocy neurons in ex vivo TG cultures. Addition of
anti-CD8a monoclonal antibody 5 d after culture initiation induced HSV-1 reactivation, as
demonstrated by production of viral late proteins and infectious virions. Therefore the
paper demonstrated that CD8+ T cells can prevent HSV-1 reactivation and importantly can
prevent reactivation without destroying infected neurons, which is a vital yet still
controversial point. The bottom line proposed by this work is that when the intrinsic
capacity of neurons to inhibit HSV-1 reactivation from latency is compromised in some
form or fashion we do not understand, HSV-1 immediate early and early protein
production activates CD8+ T cells that abort virion production.
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INF-y Induced Protection of Neurons
In other work by the Lui group, they again demonstrated that CD8+ T cells could
block HSV-1 reactivation from latency in ex vivo TG cultur�s without destroying the
infected neurons (71 ). The two reports differed in that this report establishes that CD8+ Tcell prevention of HSV-1 reactivation from latency is mediated by interferon gamma (IFN
y). The paper demonstrated that IFN-y was produced in ex vivo cultures of dissociated
latently infected TG by CD8+ T cells that were present in the TG at the time of excision.
Depletion of CD8+ T cells or neutralization of IFN-y increased the rate of HSV-1
reactivation several fold over controls. The importance of INFy was demonstrated when
TG cultures were treated with acyclovir for 4d to insure uniform latency and then
supplemented with recombinant IFN-y. This treatment blocked HSV-1 reactivation in 80%
of cultures when endogenous CD8+ T cells were present and significantly reduced or
delayed HSV-1 reactivation when CD8+ T cells or CD45+ cells were depleted from the
TG cultures. The previous point indicates that INF-y is functioning to not only augment the
CD8+ T cell response, but that it also has some sort of effect on the neurons themselves,
perhaps serving to initiate deployment of MHC molecules, which are under normal
conditions not found on neurons, thus allowing the neurons to be surveyed by the immune
system. Again, the bottom line of this report is that when neurons lose their intrinsic
capability to control HSV infection in a latent state, CD8+ T cells are present to combat the
recurrent infection and this war is also waged with the assistance of INF-y. Although our
understanding of how to prevent a HSV infection is still poor, it is clear that CD8+ T cells
and the THI cytokine INF-y are critical mediators that contain recurrent infections. It is
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plain to see that any novel vaccine, especially a therapeutic one, should be able to arm a
strong CDS+ T cell mediate response that includes INF-y.

Cross Presentation/Priming
History of Cross Presentation/Priming
Cross presentation simply stated is the process whereby exogenous antigens are
funneled into the endogenous pathway of antigen presentation. This phenomenon in vivo
has been termed cross-priming (CP) and in vitro is considered as cross-presentation (CP)
(13). The concept of CP was first put forth in 1976 by Bevan, to explain in vivo CTL
responses to minor histocompatibility antigens introduced on allogeneic antigen presenting
cells (APC) ( 13). Surprisingly, in was not until 1976 that this idea, although largely
incomplete, was put forth. For years the classic dogma surrounding antigen presentation
was that exogenous antigens could only gain access to the class II pathway of antigen
presentation while endogenous antigens were confined to the class I pathway. By 1 976
surely it was understood that humans and animals alike could control a variety of
intracellular pathogens and that CDS+ T cells and the class I pathway must have been
facilitating this control in a manner that was altogether different from the classical class I
pathway. However, classical dogma was the only way a CDS+ T cell response could arise
would be if the pathogen had infected a professional APC capable of moving to the local
lymphoid tissue and interacting with T cells. The classical dogma failed to reconcile the
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fact that CDS+ T cells were being primed to respond at sites far away from lymph tissue
and to viruses that did not infect APC. The questions must have arisen. How were CDS+ T
cells responding to the pathogen? How were the uninfected APC's delivering antigens to
activate the T cells? It would take many years for science to understand the process of CP,
which finally would answer some of these questions.

Facilitation of Cross Presentation/Priming
In order to understand this process of CP we must first understand what facilitates
the process and under what circumstances the process is functioning. Many different
substances have been reported to facilitate or augment CP of different antigens including
hsp70 (97), microsomes or microspheres (87), unmethylated repeated sequences of
cytosine and guanine (CpG) (105), apoptotic bodies or blebs (4), antibodies (30), plasmids
or DNA vaccines (59), and virus-like particles (88) to name a few. Some of these
substances like hsp70 or CpG sequences appear to also have immunostimulatory properties
that cause inflammatory cytokine production from engaging cells or represent a possible
second signal. While others like apoptotic bodies appear to only enhance the delivery of
exogenous antigens by engaging a particular receptor (3). The problem is that all of these
reports put forth evidence that indicates CP causes CDS+ T cells to be activated against the
delivered antigen, but many of the substances that augment CP are not adjuvants and
therefore those cells that engage them should not undergo maturation and migrate to the
local lymphoid tissue to engage T cells. Therefore it is important to point out that CP
apparently not only causes T cell priming, but also T cell tolerance (61, 80). Not only is it
important for the APC that is cross-priming to receive the antigen and a second signal, it is
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also important for the APC to receive the proper dose of the antigen to insure T cells are
activated and not tolerized (62). Our understanding of the outcome of cross priming is
muddled by many conflicting reports. Besides antigen dose why in one circumstance can
cross priming generate a very respectable immune response while in another similar
circumstance the result is tolerance? One thing is certain; cross priming plays an integral
role in maintaining a functional immune system in regards to both response and tolerance.

Hsp70 Biology
Conservation
Amino Acid and Structural Conservation in Heat shock proteins - Heat Shock

Proteins (hsp) have been found to be highly conserved from prokaryotes up the
evolutionary tree to eukaryotes. This family of proteins has been found to be represented in
similar forms in every organism studied (35). Evolutionarily, they represent an example of
molecular "descent with modification" at the levels of gene sequence, genomic
organization, regulation of gene expression, protein structure and function (35). Alignment
and comparison of sequences between prokaryotic and eukaryotic heat shock protein 70
(hsp70) demonstrates hsp70 from the most distant species share at least 45% amino acid
identity and over 85% amino acid similarity (20). Hsp are so highly conserved that in
many autoimmune disorders various hsp have been implicated as being cross reactive with
an autoantigen (16, 89, 96, 107). If the immune system, which is exquisitely designed to be
10

able to discern self from non-self, can not distinguish between these proteins then they
obviously are very similar and highly conserved.

Protein Folding
Nucleotide and Peptide Interactions with Hsp70 - Hsp70 is an ATPase enzyme 70kd in

size capable of interacting with the nucleotide ATP by removal or addition of phosphate.
Hsp70 carries out all of its functions by binding ATP/ADP to the N terminal ATP binding
domain (NBD). The C-terminal domain includes a peptide-binding domain (PBD) that has
broad binding specificity allowing hsp70 to interact with a massive array of proteins by
binding extended hydrophobic regions within the proteins (63). Although not fully
understood, these two domains reciprocally influence one another such that peptide
binding stimulates ATP hydrolysis and ADP binding increases the peptide affinity. As of
yet no crystal structure has been solved for hsp70, but it is believed that hsp70 has two
distinct conformations. When an ADP molecule is bound to the NBD, the hsp70 exhibits
stable peptide binding and is in one conformation; when ATP is bound, peptide binding is
relatively unstable and hsp70 adopts a second conformation (92, 102). It can be said that
ATP hydrolysis converts hsp70 to the form that has a relatively stable interaction with
nascent or unfolded proteins. Exchange of ADP for ATP results in the rapid release of
peptide and vise versa. Therefore the nucleotide status affects the peptide binding state of
the hsp70; analogously the PBD affects the nucleotide status of the ATPase domain. Once
peptide is bound to the PBD the steady-state ATPase activity of various hsp70s increases
5-fold, indicating that the conformation of the PBD affects the ATPase activity of the NBD
(37). The bottom line is that the conformation of hsp70 is influenced by binding both
11

nucleotides and polypeptide substrates (28). Exactly how the binding of the theses
substrates is coordinated at present is unclear and understanding this interdomain
communication between the PBD and the NBD will be fundamental in our understanding
of chaperones.

Co-chaperones - One important aspect of nucleotide and peptide binding in hsp70 is the

involvement of heat shock protein interacting proteins or chaperonins, such as DnaJ, GrpE,
Hip, and Bag. It has become clear that the nucleotide state of hsp70 can be influenced by
these proteins. In both prokaryotes as well as more evolved eukaryotes, DnaJ, facilitates
the ATPase activity of hsp70s by accelerating the rate of ATP hydrolysis (68). Hip, which
is found in eukaryotes, has been shown to stabilize the ADP bound form of hsp70 by
inhibiting the release of the nucleotide (48). Opposite to Hip, proteins have been identified
in both prokaryotes and eukaryotes, GrpE (68) and Bag-1(48) respectively that act as
nucleotide release factors thus stimulating exchange of ADP for ATP. Therefore hsp70 is
able to communicate through intraprotein dynamics, but also communication takes place
through protein-protein interactions.

Hsp70 Protein Interactions - What type of proteins does hsp70 bind? Analysis of 53

random proteins indicates that on average, a protein will contain an hsp70 binding domain
every 30 residues (42). Then it can be stated that every protein has many hsp70 binding
sites and therefore most proteins can actually interact with a number of hsp70 proteins at
one time. Again whether hsp70 actually interact with proteins has more to do with its
conformation and the phosphorylation state of the bound nucleotide, but the most
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important point to remember is that any protein no matter if it is of self, viral, bacterial, or
cancerous origin has many potential regions that may interact with hsp. This point will be
further explored in an additional section on hsp70 and immunity.

Protein Folding and Hsp70 -What is the function of hsp70 binding to proteins? In order

for proteins to become functionally active newly synthesized protein chains must be folded
into their unique 3 dimensional shape. How this is accomplished is not fully understood,
some of a proteins shape is obviously dictated by its amino acid sequence, however
chaperones like hsp70 are also intimately involved in protein folding. Evidence has slowly
accumulated that many newly synthesized proteins require a complex set of molecular
chaperones and their metabolic energy input to reach their native state efficiently (39, 76).
Besides simply supplying energy to ensure the proper folding of nascent proteins,
chaperones also prevent proteins from aggregating at polyribosomal sites. Nascent
polypeptides will unequivocally have hydrophobic amino acid residues exposed to solvent
in the cytosol prior to proper folding due to the fact that a protein can not fold until it has
completely emerged from the ribosome. As a consequence, many nascent protein chains
expose non-native features to solvent for considerable lengths of time making them prone
to aggregation. Left alone these polypeptides rapidly self-associate into disordered
complexes or aggregates by hydrophobic forces and interchain hydrogen bonds (3 1 , 86),
but with the assistance of chaperones they fold into their native states. Evidence clearly
show nascent polypeptides enter into high molecular weight complexes with other proteins
during chain elongation in vitro and in vivo. The nature of these complexes were
investigated and found to contain nascent polypeptides (molecular mass < 20 kDa), the
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molecular chaperone hsp 73, and other unidentified proteins that could be released from
the translationally arrested ribosomes by puromycin treatment. The complexes between the
nascent polypeptide and at least hsp73 appear to be disrupted by ATP. Collectively, this
data indicates that there may be cytoplasmic machinery, including hsp 70, which
comprises a nascent polypeptide chain binding complex crucial to ensure the proper
folding ofnew proteins (45). There are many additional reports that support the fact that
hsp70s associate with nascent poly peptides extruded from the ribosome (46, 82, 84).

Protein Transport
Exogenous Hsp70 and Protein Transport - It is clear that hsp70 becomes intimately

involved with nascent peptides and proteins during their genesis to ensure those proteins
fold correctly. As importantly or perhaps more so hsp70 or hsp in general guide and traffic
proteins throughout the cell taking them across intracellular membranes and into vesicles
targeted for release from the cell. One very interesting paper points out that when hsp70 is
added exogenously to cells, hsp70 is readily imported into both cytoplasmic and nuclear
compartments of a cell. The group exploited this observation to deliver NF-kappaB
(NFKB), a key transcriptional regulator ofinflammatory responses, to the nucleus. The
results demonstrate that a fusion protein composed of a C- terminal Hsp70 peptide and the
p50 subunit ofNFKB was directed into the nucleus, bound DNA specifically, and activated
cytokine gene expression (40).

Endogenous Hsp70 and Protein Traffic - Exogenously added hsp70 is capable of

transporting proteins throughout the cell, but what ofendogenous hsp70? It is important to
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point out that hsp70 family proteins are found throughout the cell in a number of forms and
organelles, especially the ER, as well as on the surface of many cells. The ER is a vital
organelle that directs vesicular transport of a host of proteins to the Golgi apparatus where
they are subsequently released to outside the cell. One report addressed the mechanism by
which proteins are transported across the membrane of the yeast ER. The report
demonstrated that yeast BiP, a member of the Hsp70 family resident in the ER lumen, acts
as a molecular ratchet during translocation of a secretory protein, prepro-alpha factor,
through the ER membrane (75). In addition to the previous report an additional report
addresses the transit through the ER of newly synthesized light and heavy chains of
immunoglobulins (lgs ). The report shows that light and heavy chains of lgs associate with
two endoplasmic reticulum stress proteins. Glucose related protein 78 (GRP78) a member
of the hsp70 family of proteins, binds these polypeptides, presumably through exposed
hydrophobic sequences, soon after their translocation into the ER. Glucose related protein
94 (GRP94), another endoplasmic reticulum stress protein homologous to hsp90, also
associates with unassembled immunoglobulin chains, but its interaction is biochemically,
kinetically and structurally distinct from GRP78's. (78) The previous report puts forth
evidence that not one, but two stress proteins are vital to the cell for protein transport.

Hsp70 Induction and Stress

Thermal Stress Induction of Hsp70 - During normal non-pathological times or during

times cells are under no stress the hsp family of proteins plays important roles within the
cell. However during times of stress hsp's particularly hsp70 are highly induced going
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from very low concentrations to one of the highest concentrations of proteins found in cells
(70 ).Hsps were first identified in the salivary gland DNA of Drosophila that were
mistakenly left over the week-end in an incubator whose temperature was over 40 °C.
Hence the name heat shock protein. In order to confirm the role of hsp70 in mice during
thermal stress and other times a group deleted the hsp70.l gene and the hsp70.3 gene by
replacing them with an in-frame beta-galactosidase sequence. (49) Exposure of these mice
to thermal stress resulted in the rapid induction and expression of the beta-galactosidase
gene, especially in the li�er, pancreas, heart, lung, adrenal cortex, and intestine. The
previous data reaffirms older observations in different models and indicates the importance
of hsp70 during times of thermal stress.

Tumorigenesis and Hsp70 Induction - Many reports from a variety of journals put forth

evidence that a number of various stresses in addition to heat shock do in fact cause the
upregulation of hsp70. A report by Kaur et al. showed increased expression of hsp70
during oral tumorigenesis caused by tobacco and betel. Here this group evaluated Hsp70 as
an indicator of biological stress experienced by tumor cells and used that information to
predict the clinical outcome of disease. Over expression of hsp70 protein was observed in
59% of dysplastic lesions and 74% of oral squamous cell carcinomas. (55) Therefore
during times of stress caused by cellular transformation hsp70 is induced and its expression
can in fact be used to screen for the presence of cancer.

Heavy Metal Toxicity and Hsp Induction - Exposure of cells to various heavy metals

like cadmium is known to stimulate the expression of various types of genes. These
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changes in gene expression are presumed to be related to the cellular response to heavy
metal induced toxicity. In order to better understand the mechanisms related to cadmium
toxicity, a group lead by Lee used suppression subtractive hybridization on COS-7 cells
(African green monkey kidney cells) and measured the gene expression induced by
cadmium. Hsp 10, 40, 60, 70, and 89alpha mRNAs were found to be induced by this heavy
metal, with hsp70 and the co-chaperone hsp40 showing the highest induction. Obviously a
variety of different hsp were induced suggesting that hsp play different roles in cells
undergoing cadmium toxicity. ( 66) Therefore many hsp are vital to cells undergoing stress
and their induction seives stressed cells in a variety of locations throughout the cell and in
many different metabolic pathways.

Psychological Stress and Hsp70 Induction - Obviously most humans experience the vast

majority of stress due to psychological or emotional issues. Very few of us are exposed to
toxic amounts of heavy metals, especially in this day and age, and we are not subject to
temperature extremes for long periods of time. The question that clearly arises and begs
asking - Are hsp induced or upregulated during times of psychological stress? In order to
address this issue Isosaki placed rats into an extremely small holding device where the
animals could not move for extended periods of time. (53) The data generated from this
report indicate that this treatment caused a rapid and significant increase in the level of
hsp70 mRNA and hsp70 protein in rat aorta, but interestingly had little effect on the other
tested tissues. The maximum increase in hsp70 mRNA level in the aorta was observed at
0.5-1 hr after the stress, after which time it was observed to decline. These results indicate
that exposure of rats to mild psychological stress results in the induction of hsp70,
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especially in the blood vessels. Interestingly, high stress levels in humans is closely
associated with poor cardiovascular health and heart disease, therefore it will be interesting
to see if the previous observation about psychological stress and hsp70 production in blood
vessels can in some way correlate with stress induced cardiovascular issues in humans.
Obviously discovering if there is some correlation in humans will be a tricky issue due to
the significant issues involved with not only measuring hsp70 in humans, but moreover
also actually causing humans to have some form of psychological or emotional stress.
Those interested can not exactly cram people into small tubes that allow them no
movement for long periods of time.

Viral Stress and Hsp70 Induction - In addition to psychological stress, stress brought on

by transformation of cells, physical stress such as high heat, or chemical stresses from
heavy metals like cadmium, viruses have been shown to initiate a stress response in
infected cells ( 1 9, 54, 64, 69). Jindal studied the impact of Vaccinia virus (VV) infection
on stress protein gene expression in human cells. The paper reported that infection of
human monocyte-macrophages by VV caused a dramatic decrease in levels of certain
messages like RNA encoding actin and tubulin, but mRNAs for hsp70 were substantially
increased. It was shown that the increase in hsp70 mRNA was due both to increased
transcription rate and stability relative to other cellular mRNAs. One rather interesting
point in the discussion of this paper is that expression of some of these stress proteins may
be beneficial to the virus based upon the facts that hsp70 levels are greatest at the peak of
viral gene expression and that a large fraction of cellular hsp70 is associated with VV
proteins even suggesting that hsp70 might somehow be involved in VV assembly.
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Therefore induction of hsp genes and association of hsp with viral proteins could actually
be another example of a virus co-opting cellular machinery to carry out its life cycle.
In the Liberman paper evidence points to the hepatitis C virus (HCV) E2 envelope protein
activating transcription of intraluminal chaperone proteins GRP78 and GRP94. During
HCV infection E2 as well as another envelope protein E I are targeted to the ER, but
instead of being secreted, they are retained in a pre-Golgi compartment in a partly
misfolded state. It has been well illustrated that retention of unfolded proteins with in the
ER compartment can and often does induce transcription of resident ER hsp (32). The
paper using reporter genes with GRP78 and GRP94 promoters found that E2 but not EI
protein did cause the GRP78/GRP94 report system to tum on. It was also demonstrated
that again E2, but not El protein, induces the synthesis of GRP78 from the endogenous
cellular gene as measured by western blot analysis. Using immunoprecipitation, this paper
also found that the E2 protein of HCV binds tightly to GRP78, but EI does not. In fact, this
association may explain the ability of the E2 protein to activate transcription of GRP78 and
GRP94, since GRP78 has been postulated to be a sensor of stress in the ER.
Bolt's study examined the effects of Measles virus (MV) infection of cells. Bolt's data
argues that MV infection causes upregulation in the ER of calreticulin and GRP78 and also
increased the amount of these proteins present at the cell surface. As in the previously
mentioned study with HCV, immunoprecipitation of GRP78 again demonstrated a tight
association with the viral proteins, haemagglutinin (HA) and fusion glycoprotein (F
protein) of MV. Thus, interaction with calreticulin appears vital for processing of nascent
MV F protein into its functional conformation. There appears to be clear evidence that
infection of cells by a wide variety of very different viruses induces the transcription of
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various hsp. What is less clear is why hsp are induced during viral infection? Is their
induction beneficial to the host or the virus? Evidence put forth in these papers points out
that many viral proteins not only induce hsp, but also can be found associated with hsp.
Therefore it is logical to expect that the hsp assist the viral proteins in folding correctly,
which is simply another example of how virus co-opt cellular machinery in order to
replicate, but what is also apparent is that host cells can also take advantage of these
interactions to alert the immune system to the presence of the viral invader and
subsequently mount a response against the virus, which will be discussed in get length in a
latter section on hsps and immunity. Therefore in the evolutionary arms race pitting host
against virus it appears that the virus is not the only entity capable of felonious acts. Host
and their infected cells can take advantage of viral processes to protect and maintain
themselves just as viruses can take advantage of cellular processes to maintain themselves.

Hsp70 and Immunity
The Ubiquitin-Proteasome Pathway of Antigen Processing/Presentation and Hsp70 -

Heat shock proteins are a pleiotrophic family of proteins whose functions are vitally
important to cells during times of stress, particularly hsp70. As previously mentioned
Hsp70 is highly upregulated during stress functioning in a variety of sites and performing
many tasks. In addition to the functions already mentioned and much more important to
hsp70's immunological role is the cytosolic hsp's hsp70 and hsp90 have been shown to
constitute a part of the ubiquitin-proteasome pathway (106), the pathway responsible for
degradation and recycling of outdated proteins and the processing of protein antigens into
shorter fragments capable of fitting into a MHC I binding groove. In fact it is through this
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pathway that aberrant or foreign proteins are broken down by various enzymes that
makeup the proteasome complex into class I antigens. After processing in the proteasome
the antigens are transported via the transporter associated with antigen processing (TAP)
dimmer through the membrane of the ER, where the antigens may be subsequently
processed or trimmed on the N-terminal by additional enzymes found in the ER. Finally,
after the protein has been degraded into peptides 8 or 9 amino acids in length it is loaded
onto nascent MHC class I molecules that are transported through the Golgi vesicular
transport pathway to the cell surface. Once on the plasma membrane the complex is
exposed to surveillance by naive CD8+ T cells, which if present a cell receptor (TCR)
specific for the antigen will engage the complex. If the antigen is presented in the proper
context, meaning surrounded by costimulatory molecules like B7. l,2 or CD40, the
antigen/MHC - costimulatory complex will transduce signals down the TCR as well as
through CD40L, CD28, and a host of other molecules causing the T cell to proliferate and
produce many various cytokines and chemokines. Ultimately the T cell will mount a
massive response against any cell expressing the antigen that initiated these events, which
will eliminate the pathogen and generate a population of memory cells capable of quickly
responding to the same antigen at a latter time. Through these functions hsp70 obviously
can become intimately involved with nascent foreign proteins at the ribosome or aberrant
proteins such as those found in abundance in transformed cancer cells targeted to the
proteasome.
In addition to hsp70 being involved with the classic pathway of antigen processing
that occurs via the proteasome generating antigens that are transported by TAP to the ER,
hsp70 has been reported to access an alternative pathway of antigen processing that is
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independent of TAP and the proteasome (23). The previous report demonstrates that
processing and MHC class I presentation of the hsp70/antigen can occur via either a
cytosolic {TAP or proteasome-dependent) or an endosomal {TAP and proteasome
independent) route, with the preferred pathway determined by the sequence context of the
optimal antigenic peptide within the hsp70 PBD. The indications in the report are that
hsp70 bound antigens can only gain access to one of the particular pathways depending
upon the N or C terminal sequence of the bound peptide. If bound antigens need to be
further processed they will be transported to the particular pathway capable of trimming
either the N or C terminal sequence of the antigen. It is clear that cells have evolved to take
advantage of hsp70's interaction with potential antigens and our understanding of that
evolution is coming of age. For years scientist believed that the role of hsp70 was confined
to chaperoning proteins during times of stress, however in the last 10 years our
understanding of hsp70 biology has been greatly expanded. It is now clear that hsp70 not
only function to assist in protein folding, prevent protein misfolding, as well as guiding
and trafficking proteins throughout the cell, but hsp70 has now been shown to play an
important role in alerting the immune system to the presence of potential pathological
situations and arming an immune response against that danger.

Hallmarks of Hsp70 Induced Immunity - Hsp70s carry out this role by interacting with a

variety of cells contracted by the immune system; particularly dendritic cells (DC) the
most effective antigen presenting cell. In general hsp70s are capable of binding to a DC
and causing that cell to mature and initiate the production of pro-inflammatory cytokines
or hsp70 acts as an adjuvant for cells that bind the protein. The binding of hsp70 to the DC
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also facilitates cross-priming of the antigen carried by the hsp70. Cross-priming and
adjuvanticity appear to be the hallmarks of an hsp70 guided immune response and it is
these two immune functions that give such high hope to this protein as a potential vaccine
candidate against cellular pathology, such as that occurs during viral infection and
cancerous transformation. As stated before inducible hsp70 goes from miniscule quantities
in healthy cells to being one of the most abundant proteins expressed in stressed cells (70).
The fact that hsp70 is so abundant and the idea that hsp70 binds newly synthesized
proteins as well as aberrant proteins obviously provides ample opportunity for hsp70 to
interact with potential antigens. This idea seems to be readily accepted, however just how
the hsp70 bound to antigen (hsp70/antigen) is released from stressed cells is of much
greater contention. Whether hsp70/antigen complexes are actively secreted through a
process that requires energy or whether the complex is released from apoptotic or necrotic
cells is unclear. The literature seems to sway between these ideas and others with most
evidence indicating necrotic cell death releases more hsp's and is the most immunogenic.
( 10, 77, 90) One certainty is that hsp70 and other members of the heat shock family of
proteins can be readily found interacting with antigens in tumor cells (22, 5 1 , 95), virus
infected cells (54) ( 1 9, 24, 27, 40, 44) (83) bacterial antigens ( 109) as well as antigens in
cells transformed with plasmid DNA (21). After isolation, several of these hsp70/antigen
mixtures have been shown to function as a potent vaccine against the foreign or aberrant
protein that was in the cell. (93) One thing that the previous works do validate is that in
vivo hsp's actually bind to antigens. Whether this binding was initially to assist the
pathogen or can�er cell fold proteins or if the interaction was initiated by the cell to take
advantage of the first possible interaction with antigen is unclear. Now it is evident that
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this interaction is beneficial to the host due to hsp70 ability to exit pathogenic cells and
subsequently alert immune cells to a potential pathologic situation.

Hsp70 and CD14 - Whether released from a cell dying by necrosis or apoptosis or actively

secreted by a cell hsp70 is capable of interacting with a variety of cells and a variety of
receptors on those cells. The most important aspect to consider about receptors and hsp70
is the idea that hsp70 binding causes not only cross-presentation of the antigen it is
chaperoning, but also production of various cytokines from the interacting cell, and
importantly the maturation of interacting DC's. Therefore it seems to logically follow that
hsp70 might interact with more than one receptor on the surface of the interacting cell. The
first report that identified a possible receptor for hsp70 appeared in Nature Medicine in
2000. This paper demonstrated Hsp70 binding with high affinity to the plasma membrane
of human monocytes. Once bound a rapid intracellular calcium flux and activated NFKB
led to upregulation the of pro-inflammatory cytokines tumor necrosis factor-a (TNFa),
interleukin (Il.,)-1� and Il.,-6. Furthermore two separate signaling pathways were activated
one dependent on CD14 and intracellular calcium, and the other independent of CD14 but
dependent on intracellular calcium. (5) Therefore this paper demonstrated that CD14 is at
least part of a receptor complex that binds to hsp70 and triggers the production of
cytokines.

Hsp70 a nd Toll-like Receptors - Since this report surfaced our understanding of Toll-like

receptors (TLR) has greatly increased and likewise tools to study these receptors have
expanded. TLR are expressed on a variety of cells the most important being antigen
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presenting cells like macrophages and dendritic cells. This family of receptors is
evolutionarily conserved from drosophila to man. They engage their ligand by recognizing
repeated patterns or pathogen associated molecular patterns (PAMP) such as
lippopolysaccharide (LPS) or unmethylated CpG found on the ligand, for example CpG
found in the backbone of viral and bacteria DNA binds to TLR9. (11, 25, 100) Once bound
the receptor transduces a signal through additional highly conserved proteins that have
homology to proteins found in the IL-1 receptor cytoplasmic domain such as MyD88,
IRAK, and NFKB . (2) This signal transduction initiates the production of a variety of
inflammatory cytokines and chemokines eventually leading to the recruitment and
activation of the adaptive arm of the immune response. Due to the nature of these receptors
and the fact that they recognize conserved patterns in ligands one hypothesis was that
hsp70 due to its nature and high conservation could represent a potential unidentified
ligand for one of the TLR. This hypothesis has recently been shown to be correct with
hsp70 interacting with TLR2 and TLR4. Two recent reports demonstrate that HSP70induces pro-inflammatory cytokine production that was mediated via the
MyD88/IRAK/NF-kappaB signal transduction pathway and that HSP70 utilizes both TLR2
(receptor for Gram positive bacteria) and TLR4 (receptor for Gram negative bacteria) to
transduce its pro-inflammatory signal via that pathway. (7, 104) The fact that these TLR
are involved in hsp70 mediated cytokine production does not rule a role for CD14. What's
more likely is that CD14 and TLR2/4 form a receptor complex whose components are all
critical for hsp70 adjuvant role. Importantly all of the papers related to the adjuvant role of
hsp70 fail to provide evidence for CD14, TLR2, or TLR4 playing a role in the cross
presentation of hsp70 bound antigens. An additional receptor, CD91, has now been shown
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to function in that regard meaning that hsp70 interacts with at least two distinct receptor
complexes each serving distinct and vital roles in hsp70 induced immunity.

Hsp70, CD91 and Cross-Presentation/Priming - Light has now been shed on exactly

how hsp70 facilitate the cross-priming of their chaperoned peptides. A paper appeared in
Nature Immunology that put forth evidence indicating CD9 1 , a receptor known to bind
alpha 2-macroglobulin, binds glucose related protein 96 (gp96) facilitating cross
presentation of its bound antigen. ( 1 5) Soon after an additional report from the same group
illustrated that CD9 1 also binds hsp70 and hsp90 again cross-presenting their bound
antigens. (9) Both papers demonstrate that the addition of blocking antibodies to CD9 1 or
alpha 2- macroglobulin, the previously known CD9 1 ligand, inhibits re-presentation of
chaperoned antigenic peptides by macrophages and DC. In addition the previous two
papers showed post uptake processing of chaperoned peptides required proteasomes and
the transporters associated with antigen processing (TAP) thus utilizing the classical
endogenous antigen presentation pathway. The latter paper points out that all heat shock
proteins utilize the CD9 1 receptor, even though some of the proteins have no homology
with each other, which makes the paper surprising and makes one believe it might be
proven untrue. Even if it does tum out that all hsp's do not use CD9 1 , in other words there
are separate receptors for each individual hsp these interactions are still extraordinary. It
has been shown that the amount of antigenic peptide complexed to hsp70 needed to prime
an immune response is in the femtamolar range indicating the exquisite precision of this
receptor-ligand pair, and incidentally femtamolar amounts of peptide are physiologically
relevant.
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Mycobacterium Hsp70 and CD40 - Due to the high degree of conservation found in

hsp's from a variety of sources and the fact that hsp70's have been found in every
organism studied to date (70) one would expect that hsp70 from different sources would all
bind the same cellular receptors, but that apparently is not the case. A recent report ( 108)
showed that Mycobacterium (Mtb) hsp70, but not human hsp70 is dependent on the cell
surface expression of CD40 and Mtb hsp70 stimulates mononuclear cells to release CC
chemokines. The paper points out that deletion of the CD40 cytoplasmic tail abolished, and
CD40 antibody inhibited Mtb hsp70 stimulation of CC-chemokine release. In addition,
Mtb hsp70 stimulated a variety of monocyte-derived dendritic cells to produce RANTES.
Also specific binding of CD40 transfected cells to Mtb hsp70 was demonstrated by surface
plasmon resonance. Finally the paper pointed out that Mtb hsp70 coimmunoprecipitation
with CD40 indicating a physical association between these molecules. The results of the
paper suggest that CD40 is important in Mtb hsp70 binding and stimulation of the
chemokine RANTES.

Adjuvants and Adjuvant Property of Hsp70 - In addition to hsp70 facilitating cross

presentation of bound antigens by interacting with CD9 l hsp70 also plays an important
role as an adjuvant, which was only briefly discussed above. As mentioned hsp70 interacts
with a receptor complex composed of CD 1 4, TLR2, and TLR4 causing the production of
various soluble factors that mediate immunity. Adjuvants are commonly used in vaccines
to augment their effectiveness. They are thought to function in one of two ways.
Adjuvants, like alum, function by creating deposits of antigen at the site of injection that
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led to a slow sustained release of the immunogen. The other function is to non-specifically
activate immune responses that assist adaptive responses. Adjuvants that non-specifically
activate immune response, like CFA, usually contain bacterial endotoxins, which result in
increased pathology, and toxicity. Adjuvants can also direct the type of immune response
that is generated. Alum, the only adjuvant approved for use in humans, skews the immune
response towards a T-helper type 2 (Th2) responses. Th2 responses are characterized by
secretion of Th2 cytokines and generation of lgG1 and IgE antibodies, but weak or absent
CTL responses. In contrast, strong cell mediated immunity is associated with Th I
responses. This type of response is crucial for control of intracellular pathogens. (1)
Evidence for hsp70 indicates an ability to promote a Thl type response characterized by
induction of the pro-inflammatory cytokines IL-12 and TNF-a (5, 103), functioning to
strengthen CTL responses. Since currently no adjuvants approved for human use can skew
an immune response towards Th1 type response, use of the endogenous protein hsp70
holds promise.
What makes the previous claims of hsp70 functioning as an adjuvant significant is
that hsp70 free of peptide was shown to transduce a signal to cells leading to cytokine
production. (5, 103) Therefore, it can be stated that hsp are functioning as natural
endogenous adjuvants. (67) This has vast implications because it is a role for hsp and a role
independent of peptide presentation and implies hsp70/antigen mixtures are capable of not
only delivering the first signal that activates T cells via the TCR, the peptide, but this
mixture also delivers the all important second signal that causes upregulation of important
co-stimulatory molecules and inflammatory cytokines and chemokines, leading to the
activation of T cells and not their tolerance.
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Naive vs. Mature Dendritic Cells - Naive antigen presenting cells are phenotypically

distinct from their mature counterparts. Naive APC's are highly motile and bestowed with
very high phagocytic capabilities allowing them to sample their environment with great
tenacity. In addition naive APC display very low amounts of co-stimulatory molecules like
CD40, B7. 1 , and B7.2 as well as MHC molecules. Once these cells sense danger in their
surroundings they initiate a programmed set of events that promotes the migration of APC
to local lymphoid tissue, up-regulation of the previous co-stimulatory molecules and MHC,
and lose of phagocytic abilities. Maturation enables the APC to effectively activate T cells
specific for the peptides they are presenting.

Substances that cause Dendritic Cell Maturation - In addition to adjuvants functioning

to initiate the production of a variety of cytokines and chemokines good adjuvants also
cause the maturation of antigen presenting cells. Exactly what induces the maturation of an
APC seems to be an almost infinite list that expands almost daily. Polycyclic aromatic
hydrocarbons such as benzoapyrene, (65), the polysaccharide of hyaluronic acid produced
during inflammation(l O 1 ), Human immunodeficiency virus (HIV-I ) Nef protein, (4 1 ) the
biologically active HIV- 1 Tat protein, (34) the imidazoquinoline compounds imiquimod
and R-848, which are low-molecular- weight immune response modifiers, (4 7)
monophosphoryl lipid A(52), LPS, and a veritable plethora of other compounds are all able
to cause APC to switch their program from an immature phenotype into a mature
phenotype. What all of these compounds have in common is the ability to bind to TLR or
seive as their ligand and subsequently initiate the maturation of DC. The idea that TLR
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engagement by a ligand induces the maturation of DC indicates that interaction between
hsp70 and TLR should also initiate DC maturation.

Hsp70 and DC Maturation - In fact several papers due lend support to endogenous hsp70

functioning to initiate the maturation of DC. Necrotic, but not apoptotic cell death leads to
release of hsp like gp96, calreticulin, hsp90 and hsp70. These various hsp stimulate DC
and macrophages (M�) to secrete cytokines, and induce expression of antigen-presenting
and co-stimulatory molecules on the DC, or cause their maturation. What is interesting
about this report is that the hsp gp96 and hsp70 act differentially, and each induces some
but not all cytokines and costimulatory molecules. (10) As hsp are abundant and soluble,
their presence in the extra-cellular milieu and their ability to activate APC constitutes an
excellent mechanism for response to cell death by necrosis. Cell death by necrosis, which
results in the release of all contents that were previously within the cell, is typically
associated with inflammation in contrast to apoptosis that by its nature represents a silent
death due to the fact that after death all cellular material is maintained within apoptotic
blebs hidden from surveillance by the immune system. Therefore the release of hsp from
necrotic cells, which obviously lysed due to a pathologic situation, is a potent mechanism
to alert the immune response to potential danger.

Apoptosis, Necrosis, and Hsp70 - It would be remiss not to include an additional report

about the consequenc� of cell death and hsp involvement in that death. Bhardwaj et al.
have identified additional distinctions at the level of DC between the two types of death
that occur and which type influences the induction of immunity. (90) As stated previously
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DCs must undergo changes termed maturation to act as potent antigen-presenting cells
capable of priming a T cell response. Bhardwaj's report investigated whether exposure to
apoptotic or necrotic cells affected DC maturation. The report supported Basu's work that
found only exposure to necrotic cells not apoptotic cells induces maturation of DC. The
report from Bhardwaj demonstrated that exposure of DC to necrotic cells, but not apoptotic
cells caused the DC to mature. Exposure of DC to necrotic cells led to high expression
levels of the DC-restricted markers CD83 and lysosome-associated membrane
glycoprotein (DC-LAMP) and the costimulatory molecules CD40 and CD86. Furthermore,
the DC's exposed to necrotic cells develop into powerful stimulators of both CD4+ and
CDS+ T cells. The most important point of this paper is that it distinguishes between the
effects of exposure to necrotic cells and simple lysates of apoptotic cells on DC
maturation. Upon exposure to lysates or supernatants of necrotic transformed cell lines,
human DC undergo maturation. In contrast, DC exposed to apoptotic transformed cell lines
or lysates of primary cells remain in an immature state. When the supernatants of necrotic
transformed cell lines were analyzed they were show to be enriched in the hsp, hsp70 and
gp96, in contrast to supernatants of primary cells. Likewise, cells from a variety of primary
human tumors contained considerably higher levels of hsp than their normal autologous
tissue counterparts. The maturation effect of tumor cell lysates was abrogated by treatment
with boiling that would denature all proteins and render them useless, proteinase K an
enzyme that degrades proteins, and geldanamycin, an specific inhibitor of hsp70 and gp96,
suggesting that hsp70 and gp96 rather than endotoxin or DNA were the factors responsible
for DC maturation. These results suggest that the maturation activity inherent within tumor
cells and lines is mediated at least in part by hsp. The release of hsp in vivo as a result of
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cell injury promotes immunity through the maturation of resident DC via their interaction
with hsp and the antigens they carry.

Hsp70 Based Vaccine and DC Maturation - The above reports point to hsp70 playing an

important role in in vivo to initiate the maturation of DC. There are additional reports that
indicate recombinant hsp complexed to antigen and administered as a vaccine can also
cause DC maturation. One report by Srivastava demonstrates that immunization of mice
with the hsp, gp96, but not control proteins leads to 5- to 7-fold enlargement of lymph
nodes draining the site of administration. The enlargement was shown to be the result of
accumulation of large numbers of mature CD1 1c+ DC, but not T or B cells. The report
also shows that the increase in size and cell number was time-dependent; the draining
lymph nodes reach their peak size between 12 and 24 h after injection and regressed to
their normal size between 48 and 72 h after injection. (14)

In vitro Hsp70 and DC Maturation - An additional report puts forth evidence that

indicates in vitro hsp70 is able to persuade immature bone marrow derived monocytes to
switch to a mature phenotype. (60) The previous report demonstrated that rhsp70 binds to
· immature dendritic cells derived from monocyte precursors and induces ·their maturation as
evidenced by an increase in CD40, CD86 and CD83 expression. Immature DC stimulated
to mature with rhsp70 show an enhanced ability to present peptide and activate CTL's
specific for that peptide. In addition it was shown that mature DC did not bind rhsp70,
suggesting that DC down-regulate expression of the receptor for hsp70 after maturation. A
final intriguing point of this paper was the constitutively expressed hsp, hsc70, had little or
32

no effect on the maturation of immature DC nor did it reduce the differentiation of
monocytes into DC. The previous notion about hsc70 is very intuitive due to the fact that if
a constitutively expressed protein that is present in high levels in healthy cells had these
adjuvant properties uncontrolled inflammation and severe auto-immune disorders would
arise. The findings in many of the previous papers demonstrate the specific ability of
rhsp70 or endogenous hsp70 to induce the maturation of immature DC.

Hsp70, Peptide Affinity and Hybrid Peptides - It would be remiss not to include the

concept of peptide affinity for hsp. Only a subset of peptides may bind to hsp70 with high
affinities depending on the relevant hydrophobicity of those peptides (38). This marked
difference in affinity between hsp70 and peptide can potentially limits the repertoire of
peptides available to induce a potent CTL response by a hsp70 based immunization
strategy. Potential motifs of polypeptides that can associate and bind with increased
affinity to hsp have been determined via an affinity panning technique using a
bacteriophage library, specifically motifs for binding to Bip, an hsp70 chaperone family
member located in the endoplasmic reticulum that contains an homologous peptide binding
site to inducible hsp70 (1 8, 38). Based on these findings construction of hybrid peptides
consisting of a high-affinity ligand for the peptide-binding site of hsp70 joined to various
CD8+ T cell epitopes by a glycine-serine-glycine linker were constructed (8 1 ). The
peptides contained a defined CD8+ T cell epitope in C57BL/6 mice derived from chicken
ovalbumin (SIINFEKL), and the gB protein of HSV (SSIEFRAL), linked to a peptide
domain with a reported 20 fold higher affinity for hsp70 proteins. The previous paper
showed immunization with hybrid peptides complexed to mouse hsp70 effectively primed
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specific CTL responses in mice and more importantly were more potent than the cognate T
cell epitopes alone with hsp70. The report generated evidence that in vivo immunization
using hsp70 and hybrid peptides caused the rejection of tumors expressing the SIINFEKL
antigen with greater efficacy than immunization with cognate peptide epitope plus hsp70.

Heat Shock Proteins and Autoimmunity -Heat shock proteins, the most conserved
molecules known to date, may also function as immune targets during infection. Due to
their ubiquitous distribution and high degree of structural similarity, hsp are potential
target antigens in autoimmune diseases. In fact, microbial hsp are among the most
dominate antigens recognized in an immune response. Due to the high probability that
microbial hsp will be antigens and because these proteins are so similar there is a high
chance of cross-reactive responses to epitopes shared by host and microbe hsp. Many
reports do point out that various hsp family members are considered to be potential T and
B cell autoantigens in a plethora of autoimmune disease models (8, 33, 36, 73, 89, 96)
( 107) ( 16), which indicates that even the immune system is unable to discern differences in
these proteins. The Steinhoff paper describes induction of intestinal inflammation and
pathology following transfer of hsp60-reactive CD8+ T cells into mice, emphasizing a link
between infection and autoimmune disease. Salvetti' s work puts forth evidence that
supports an association between immunity against the 70-kd heat shock protein of M.
tuberculosis (Mthsp70) and development as well as progression of multiple sclerosis (MS).
By generating and testing T cell clones reactive to Mthsp70 from healthy patients and
patients with MS as well as using peptide mapping techniques to determine cross
reactivity, the previous report determined that immune responses against Mthsp70 could
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contribute to the pathogenesis of MS by hsp70 acting as potential autoantigens in MS (89).
Primary biliary cirrhosis (PBC), a chronic cholestatic liver disease associated with
autoimmune disorders, has an unknown etiology. However there does appear to be
evidence that Mycobacterium gordonae is associated with the disease. A report by Vilagut
characterizes immune recognition of two M. gordonae membrane polypeptides of 70-65
and 5 5kD that are cross-reactive with the two major mitochondrial proteins from patients
with PBC. It was subsequently determined that the 65-70kD protein was Mthsp65. Using
competitive immunoblotting data from this paper showed that binding of a monoclonal
antibody to human hsp65 was prevented by preincubation with. sera from patients with
PBC, but not with sera from healthy subjects. Furthermore, a monoclonal antibody to
human hsp65 protein recognized the main mitochondrial autoantigens of PBC. These data
indicate the existence of cross- reacting epitopes contained on M. gordonae hsp65 and the
main mitochondrial antigens in patients with PBC. Diabetes, which is a classical
autoimmune disease, is the result of immunopathology to the insulin producing �-cells of
the pancreas. Those studying the various human diabetes diseases use the non-obese
diabetic (NOD) mouse as a model. As in the previous reports Birk describes the onset of �
cell destruction with the spontaneous development ofT cells reactive to members of the
hsp60 family of proteins, including Mycobacterial and the human hsp60. Diabetes in the
NOD mouse occurs spontaneously without prior immunization. This paper suggests that
the anti-hsp60 T cells involved in the autoimmune diabetes of NOD mice could reflect
molecular mimicry between Mthsp60 and a �-cell hsp60 sharing similar T cell epitopes.
The literature is absolutely chalked full of references indicating T cell and antibody
responses mounted against prokaryotic hsp to protect the host from the pathogen often lead
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to autoimmunity due to cross reactivity between the highly conserved hsp from the
prokaryote and their eukaryotic counterparts. Those studying the various human diabetes
diseases use the non-obese diabetic (NOD) mouse as a model. As in the previous reports
Birk describes the onset of �-cell destruction with the spontaneous development of T cells
reactive to members of the hsp60 family of proteins, including Mycobacterial and the
human hsp60. Diabetes in the NOD mouse occurs spontaneously without prior
immunization. This paper suggests that the anti-hsp60 T cells involved in the autoimmune
diabetes of NOD mice could reflect molecular mimicry between Mthsp60 and a �-cell
hsp60 sharing similar T cell epitopes. The literature is absolutely chalked full of references
indicating T cell and antibody responses mounted against prokaryotic hsp to protect the
host from the pathogen often lead to autoimmunity due to cross reactivity between the
highly conserved hsp from the prokaryote and their eukaryotic counterparts.
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Chapter II
Materials and Methods

Materials
Mice
Four-to-Five week old female C57BL/6 mice (H-2b) purchased from Haraln
Sprague-Dawley (Indianapolis, IN) were used in all experiments. The investigators
adhered to guidelines set forth by the Committee on the Care of Laboratory Animal
Resources, Commission of Life Sciences, and National Research Council. The facilities
used were accredited by the American Association for Accreditation of Laboratory Animal
Care.

Antigens
All peptides were synthesized by Research Genetics (Huntsville, Ala) or the
Mojave Corporation (New Jersey). The sequences used in the various studies included the
H-2b immunodominate epitopes from HSV and Chicken Ovalbumin, SSEIFRAL and
SIINFEKL, respectively. In addition, hybrid peptides were purchased containing the
former peptides linked to HWDFAWPW. These peptides will be designated BipOVA or
OVABip and BIPHSV or HSVBip depending upon if the Bip sequence is linked to the N
or C terminus. Also the hybrid peptide used in the memory experiment is designated as
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JavalinSSEIFRAL, which is the name given to the Bip sequence by the company who
supplied some of the peptide, Mojave Therapeutics. These peptides contain a gsg linker
that attaches the hybrid sequence to the peptide.

Cells
MC-38 fibroblast (H-2B) and EMT-6 fibroblast (H-2D) were cultured in
Dulbecco 's Modified Eagle Medium (DMEM) containing 10% heat inactivated fetal calf
serum (FCS), 1% gentimyicin, and 2mM L-glutamine. DC 2.4 dendritic cell (H-2B), B-32
T-cell hybridoma (H-2B), JAWS II Macrophage (H-2B) were cultured RPMI 1640
containing 10% FCS), 1 % gentimyicin, and 2mM L-glutamine.

Methods
Immunizations
In the memory experiment C57BL/6 mice in groups of four were immunized with
. 1, 1, 2, or 5µg ofSSIEFARL/hsp70 or BipSSIEFRAL/hsp70. In addition, individual
groups were immunized with either 5µg of SSIEFRAL, hsp70, or BipSSIEFRAL. The
immunizations were done intraperitoneally on day O and day 7. 60d after the first
immunization the mice were sacrificed and subjected to various assays. Intraperitoneal
route was chosen after experimenting with intramuscular and footpad injections.
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Cell Surface Staining for FACS Analysis
The procedure below for FACS analysis is general and applicable to any and all
antibodies used for cell surface staining as well as any and all cell types used in those same
regards. The types of cells used for FACS will always be indicated with the appropriate
data throughout this thesis. Whether cells have been derived from tissue culture, spleen, or
lymph nodes it is important to practice proper aseptic techniques and most importantly it is
critical to keep the work on ice except the few places where noted. These steps will ensure
the cells maintain their integrity as well as reduce background and non-specific staining.
Initially, the cells must be collected and spun down at 1600 rpm for 10 min. in a proper
tube or plate. Next, the erythrocytes (RBCs) can be lysed with a Tris sodium chloride
(NH4Cl) solution {lml/107cells) at 37°C for 5min. The lysis is then quenched by addition
of RPMI or DMEM (2x volume ofNH4Cl). After quenching the cells are spun down as
before, media is poured off, and the cells are resuspended in 20 ml of fresh media. The
previous step is repeated 2 xs to make certain all vestiges of the NH4Cl solution is
removed. After washing the cells are counted and resuspended in FACS buffer (3g BSA
and 0.0lg sodium azide in 100ml of lx PBS) at a concentration of lx107 cells/ml. The
cells are allowed to equilibrate for 20 min. in the FACS buffer prior to being spun down
and resuspended in FACS buffer. Next, 100µ1 aliquots of cells, which contain 106 cells,
are placed into individual wells of a 96 well plate. I 00µ1 of anti Fe receptor antibody at a
concentration of 2µg/ml in FACS buffer is added to each well and incubation is carried out
for 30 min. on ice. After 30 min. the plates are spun down at 1600 rpm for 10 min. the
media is carefully removed by aspiration or simply pouring off excess and then all samples
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are washed 2 times with FACS buffer. Next appropriate FITC or PE labeled antibodies
(l0µg/ml) were added to FACS buffer to make a bulk amount and assure the proper
concentrations of each antibody was added to individual samples. Next, 100 µl of FACS
buffer containing the appropriate labeled antibody was used to suspend the samples. In
general each individual sample was broken down in triplicate and added to the 96 well
plates so that la, 2a, 3a, and 4a where all replicates of the same sample. The replicates
were then stained with various antibodies of interest, isotype control antibodies, and one
replicate always remained unstained. Each sample was allowed to incubate with the
antibodies on ice for 30 min. Finally, after incubation with the antibodies all samples were
washed 2 xs in FACS buffer prior to transferring the samples into individual FACS tubes
for subsequent analysis. FACS analysis was then carried out with a FACS scan machine
(Becton-Dickenson).

Intracellular lnterferony Staining
To enumerate IFNy producing cells, intracellular cytokine staining was performed
as previously described (58). In brief, 106 freshly expanded splenocytes were cultured in
flat-bottomed 96-well plates. Cells were left untreated, stimulated with HSV peptide
SSIEFARL (0.1 µg/ml), or treated with PMA (lOng/ml) and ionomycin (500ng/ml),
incubated for 6h at 37 °C in 5% CO2. Brefeldin A was added for the duration of the culture
period to facilitate intracellular cytokine accumulation. After this period cell surface
staining was performed, followed by intracellular cytokine staining using the
Cytofix/Cytoperm kit (PharMingen, San Diego, CA) in accordance with the
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manufacturer's recommendations. All antibodies were purchased from PharMingen and
processed cells were analyzed with FAC SCAN and CellQuest software.

Tetramer Staining
Spleenocytes were harvested from immunized or control mice at indicated time
points. The spleens were homogenized into a single cell suspension and RBC' s were lysed
using ammonium chloride. Next, the cells were counted and placed into 96 well plates.
Each well contained 1 x 106 cells. Prior to the addition of the cells each well was loaded
with 50u of recombinant 11-2 and 50 µl of RPMI 1640 containing a 2.5 µg/ml
concentration of either the relevant peptide the cells are responding against or an irrelevant
peptide as a control. The cells are then allowed to expand for 5 days at 37 ° C in 5% CO2.
After the five day expansion the cells are collected and washed 2X in FACS buffer
containing 3% BSA and .0011% sodium azide. Next the samples are all incubated with Fe
block, to eliminate non-specific binding, for 20min and washed. After washing the cells
are placed on ice and stained with antibodies and/or tetramers. Each mouse had three
samples stained with the indicated antibodies from Pharmingen (San Diego, CA), one
sample is the isotype control staining with rat IgG-FITC or rat IgG 1-PE, another sample is
CD8a-FITC, and finally CD8a-FITC and the SSIEFARL Tetramer conjugated to PE. The
samples are allowed to incubate for 20-30min on ice and then they are washed in FACS
buffer at least 2X, prior to loading in FACS tubes to be analyzed.
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Interferony ELISPOT
Prior to harvesting immune or control spleenocytes ELISPOT plates (Millipore
Multiscreen Plate) were coated with sterile carbonate buffer containing 2µg/ml of rat
amouse Interferon y antibody (Pharmingen - San Diego, CA) ,known as the capture
antibody, overnight at 4 °C. These plates were then washed 3X in cold sterile PBS prior to
blocking with 100µ1/well of RPMI or DMEM for 2h at 37 °C. During this incubation
spleenocytes from immunized or control animals were harvested, homogenized into single
cell suspensions, RBC's lysed, cells were counted, and placed on ice. After blocking
irrelevant and relevant peptide were added to respective wells at a concentration of 5 µg/ml
of media. After which 1 00µ1 of spleenocytes from individual mice were added to the wells
at a concentration of 1 x 1 06 diluted to 1 .25 x 1 05 per well. The plates were then allowed
incubate at 37 °C and 5% CO2 for 48h in a vibration-free incubator. Each sample was done
in triplicate for both the reactive and irrelevant peptide so that an average could be taken
and background could be subtracted from the results. After the incubation the plates were
washed 3X in sterile I % PBS and 3X in I % PBS containing 0.05% Tween-20. After
washing the detection antibody or biotin labeled rat amouse Interferon y (Pharmingen San Diego,CA) was added to each well at a concentration 2µg/ml in 3% BSA 1 % PBS.
Again this was allowed to incubate at 4°C overnight. After incubation the plates were
washed 3 xs with 1 % PBS containing 0.05% Tween-20 and patted dry onto paper towels.
After drying 1 00 µI of streptavadine peroxidase diluted 1 : 1 000 in 3% BSA 1 % PBS was
added to each well and allowed to incubate at room temperature for 1hr. After incubation
the plates were washed 7 xs in 1 % PBS containing 0.05% Tween-20 and dried. Next 200µ1
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of substrate buffer (lAEC (3-amino-9-ethyocarbazole) tablet dissolved in 2.5 ml of
dimethylformamide was added to 47.5 ml of 50mM acetate buffer pH5.0 immediately
prior to use 25µ1 of 30% H202 must be added) was added to each well and left until color
developed (~7min). After color development plates were copiously washed with H20 ( 1015 xs), and allowed to dry overnight at room temperature. The next day the plates were
counted using a dissecting microscope.

Production of Recombinant Mouse Hsp70
The mouse hsp70 gene, hsp70. l, is a highly stress inducible member of the heat
shock protein family of proteins. The mouse hsp70 .1 gene, which was cloned from a
mouse library made from partially digesting mouse kidney DNA from the AJ mouse strain,
was inserted into a pUC vector by Calderwood et al. (50) and supplied to the Rouse lab
second hand. In order to facilitate the production of mouse hsp70.1 protein it was prudent
to remove the gene from the antiquated pUC vector and insert the gene into a more up to
date protein expression vector, pET22b. Therefore a PCR based strategy was designed
utilizing the 5 ' primer CGATCATATGGCCAAGAACACGGCGATC and the 3' primer
CGTACGGATCCTTCTCACTAATCCACCTCCTCGATGG to amplify out the Nde
1/BamHI fragment from pUC8 containing the hsp70. l gene. The PCR utilized basic
reagents with 35 cycles (94 °C melting lmin, 55 °C annealing 2min, 72°C extension 3min.)
to generate the amplicon containing the hsp70 gene. After amplification the fragment was
extracted using a GeneClean kit (Sigma). Next, 3µ1 of the PCR product was added to a
digestion reaction containing 40µ1 of deionized H20, 5µ1 of l0x buffer, and 2µ1 of the
restriction enzyme Ndel (Sigma) to produce a 5' Ndel compatible site. After 2hr
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incubation at 37 °C the fragment was ethanol precipitated and subjected to an additional 3'
digestion. The 3' digestion was carried out using 2µ1 of BamHI_(Sigma), 22µ1 of deionized
H20, 3µ1 of lOx buffer, 3µ1 of BSA, and 3µ1 of the PCR product. Concurrent reactions
using the same conditions were carried out with pET22b. After digestion all products were
ethanol precipitated and subsequently run on an agarose gel to insure the fragments were
all the correct size. After precipitation the digested fragment and pET22b vector were
ligated together using T4 DNA ligase () to produce the hsp70 protein expression vector
pET22b/hsp70.1. To ensure that the vector contained the hsp70.1 gene, E.coli DH5a was
transformed with the vector using a simply heat shock method. Heat shock transformation
was carried out by thawing DH5a on ice, mixing lµg of the vector with 50µ1 of DH5a,
placing the mixture into a 42°C water bath for lmin., and then adding the transformed cells
to 950µ1 of luria broth (LB- Sigma). The LB/cell mixture was then paced on a shaker at
37 °C for 1hr prior to plating the cells onto LB agar plates containing lO0µg/ml of
ampicillin (Sigma}. The plates were then allowed to incubate overnight after which time
colonies were selected and screened for the presence of the pET22b/hsp70.1 vector. In
order to screen for the vector transformants were grow up in 10ml of LB containing amp
until the optical density of the mixture was turbid. Next, the cells were used in a Miniprep,
which isolated plasmid DNA. After isolation the plasmid DNA was digested with Ndel
and BamHI and subsequently run out on a 1% agarose gel to confirm the presence of the
hsp70.1 gene. After the vector was screened and the presence of the gene was confirmed�
the plasmid was sent to the DNA sequencing facility at the University of Tennessee, which
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utilizes the dideoxynucleotide method, to reconfirm the presence of the gene and to ensure
no alterations in its sequence had arisen during cloning.
After the sequence was confirmed BL21 Star, which is an e. coli engineered for
optimal protein production, was transformed with the pET22b/hsp70.1 vector. The cells
were grown overnight in LB broth supplemented with 100µg/ml of ampicillin. Fresh,
prewarmed media was adjusted to 1% culture using the overnight culture, and the culture
was then grown at 37 °C in a shaking water bath (225 rpm) to an OD595 of0.6. The culture
was then adjusted to 0.1 mM isopropyl-P-D-thiogalactoside {IPTG) and incubated for an
additional 3hr. at the same conditions. The culture was centrifuged and the supernatant
discarded. The cell pellet was resuspended in hypotonic buffer F containing protease
inhibitors and placed into a French Press. After pressing the sample was spun at 12,000
rpm for 30min. The supernatant was collected and passed over an ATP column (Sigma).
Hsp70 was eluted with a 5mM ATP buffer and collected. Next the sample was passed over
a Q sepharose column that was washed with 110mM NaCl and fractions were eluted with
200mM NaCl. Fractions were checked for concentrations and purity using a
spectrophotometer (A280). Fractions were then pooled and stored at -80 °C for later use.

Other Heat Shock Proteins
The recombinant human heat shock protein was purchased from Stressgen (British
Columbia, Canada). CSS 1 was purified from 14-day-old pea (Pisum sativum) cotyledons
applying an affinity chromatography method similar to that used to purify Bovine taurus
Hsc70 (91). Fractionated stroma from pea was prepared as described previously (74) and
diluted 1: 10 with buffer M (20 mM 4-(20hydroxyethyl)-1-piperazineethanesulfonic acid
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(HEPES) pH 7.5, 20mM NaCl, Mg(Oac)2, lmM dithiothreitol (OTT), and 0. 1% (v/v)
Triton X-100). Next, the entire sample was loaded onto an ATP-agarose column (Sigma
Aldrich, St. Louis) pre-equilibrated with buffer M at 4 °C. The column was washed
exhaustively with buffer M, then buffer M containing 1 M NaCl, and finally buffer M
again. CSS 1 was then eluted with 10 mM ATP in buffer M titrated to pH 7.5. Authenticity
of CSSl was demonstrated via cross-reactivity on a western blot probing with a polyclonal
DnaK antibody serum. Eluted fractions containing CSS 1 were dialyzed exhaustively and
concentrated into buffer M by ultrafiltration against a 30-kD molecular mass cutoff
membrane, aliquoted, and stored at -85 °C.

DNA Sequencing
DNA sequencing was performed at the University of Tennessee, Knoxville
Molecular Biology Resource Facility using an ABI (PE Applied Biosystems, Inc., Foster
City, CA) model 373A automated DNA sequencer and the ABI prism dye terminator cycle
sequencing kit (PE Applied Biosystems, Inc.). Cycle sequencing reactions were carried out
using approximately 400ng of plasmid DNA and 5pmole of primer in a GeneAmp PCR
system9700 thermal cycler (Perkin-Elmer Corporation, Norwalk, CT), as directed in the
ABI prism kit.

Complexing Peptide and Hsp70
The loading of mouse and human hsp70 to either the hybrid peptides or the cognate
class I peptides were performed in similar manners. The hsp70 and peptides were
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incubated together in PBS containing lmM KCl, 2mM MgC12, and lO0mM ATP for 45
min at room temperature. The ATP was added initially to remove any residual peptide that
conceivability could remain bound to the protein from its production in E. coli. lmM ADP
was added, and the incubation was extended for an additional 30 min. This complex was
then used to immunize mice. However for in vitro work additional steps were required to
remove any residue free peptide from the mixture to insure responses were due to cross
presentation of the peptide and not from simple displacement of endogenous peptides
bound to MHC molecules all ready present on the surface of interacting cells. The removal
of the free peptide was accomplished by extensive washing using a Centricon 30K column
(Amicon), which contains a filter that allows anything under 30 kilodaltons to flow
through the column. The washings were carried out until the residual peptide was
calculated to be in the picomolar range.

Enzyme Linked Immunosorbent Assays
Spleenocytes were aseptically removed from C57BL/6 mice. The spleens were
homogenized and made into a single cell suspension and subsequently treated with
ammonium chloride containing Tris buffer for 2-3 min at 37 °C to remove the erythrocytes.
Next, the suspension was plated to 75cm flasks and incubated at 37 °C in 5% CO2 for 2 to
3 hours. After incubation the media was poured off and the flasks were copiously washed
with RPMI containing 10% FCS after which fresh media was added. A cell scraper was
then used to remove all adherent cells from the plastic flasks. The adherent cells have been
well established to be a mixed population of dendritic cells, macrophages, and B cells.
These cells were collected and washed after which they were concentrated to 107 per
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milliliter of media. The cells were then added to a 96 well culture dish so that each well
contained 100ul of media containing 106 cells. Then various concentrations of the
indicated hsp70 were added to each well. The cultures were allowed to incubate for 24
hours at 3 7°C in 5% CO2. The supematants were collected and screened for the presence
of TNFa, IL-6, and 11-12 by cytokine ELISA as previously described (Manickan 1995).
Briefly, ELISA plates were coated with various capture antibodies (rat anti-mouse 11-6,
1NFa, or IL-12, Pharmingen) at a concentration of 2µg/ml in carbonate buffer (NaHCO3
pH 8.2) at 4 °C overnight. ELISA plates were then washed 3x with PBS containing 0.05%
Tween-20 pH 7.2 (PBST) and subsequently dried on paper towels. Next, the plates are
blocked with 3% bovine serum albumin in 1 % PBS (BSA) for 2h at 37 °C. After blocking,
the plates were again washed with PBST and dried prior to the addition of samples and
cytokine standards for 11-6, 11-12, or TNFa. The starting concentration of each standard
was 2ng/ml that was serially diluted down the 96 well plates. The samples and standards
were stored overnight at 4 °C. Next, the plates were washed 4 xs in PBST and dried prior to
the addition of biotinylated rat anti-mouse IL-6, TNFa, or 11-12 (Pharmingen) at a
concentration of l µg/ml in BSA. Plates were incubated for one hour at 37 °C washed 6 xs
in PBST and dried prior to the addition of 100ul of a solution containing Avidin
peroxidase in BSA (1:2000 concentration, Zymed, South San Franciso, CA) was added to
each well. After 30 min. at room temperature the plates were washed 8X and dried prior to
development. For color development 10 µl of 30% H202 was added to 10 ml of 2,2-azino
Bis 3 ethylbenzthiazoline-6-sulfonic acid (ABTS, Sigma) and 100 µl of this solution was
added to each well. The color development proceeded in dark for 10 min. at which time the
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plates were analyzed using a Spectro-Max 430 plate reader that measures the amount of
light at 405 nanometers that passes through each well or the optical density of each well.
Cytokine concentrations were determined extrapolating from the standard curve.

Confocal Microscopy
DC 2.4 cells were haivested from a cell culture flask and placed at a concentration
of 106/ml into a 96 well plate. Next, the cells were pulsed with recombinant human hsp70
(StressGen - Victoria, British Columbia) coupled to the H-2b immunodominate peptide
from chicken ovalbumin, SIENFEKL, at a concentration of 1 µg/106 cells. This reaction
was allowed to incubate for lb at 37 °C in 5% CO2. After incubation the cells were placed
on ice and washed in FACS buffer 2xs. Next the cells were stained with PE labeled ahsp70
(StressGen - Victoria, British Columbia), and coated onto microscope slides for evaluation
under the confocal microscope.

Magnetically Activated Cell Sorting
CD 1 1 c+ dendritic cells were positively selected using a magnetically activated cell
sorter (Miltenyi Biotec). Whole spleens were aseptically removed from C57BL/6 mice and
subsequently homogenized into a single cell suspension, RBC's were lysed using
ammonium chloride, and the cells were counted. After counting, the cells were spun down
(1250 rpm for l Omin.) and the media was decanted so that fresh MACS ( 1 %PBS and 0.5%
BSA) buffer could be exchanged for either DMEM or RPMI, whichever media used during
spleen haivest. After exchange the cells were washed in MACS buffer 2 xs to remove any
residual growth media. Next, the total cell population was suspended in 450µ1 of MACS
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buffer and 50µ1 ofmagnetically labeled rat amouse CD l lc+ antibody (Miltenyi Biotec)
was added by slowly pipetting up the mixture until it was thoroughly mixed. The cell
antibody mixture was then placed at 4°C for exactly 20min. After incubation 9.5ml of
fresh MACS buffer was added to the mixture, which was thoroughly mixed again,
subsequent to spinning at 1250 for l Omin. at 4 °C. The mixture was then washed two more
times, each time in 10ml offresh MACS buffer. After washing the cells were then
suspended in 500µ1 ofMACS buffer, which contained up to 108 cells. Prior to using a LS+
separation column (Miltenyi Biotec) the column must be equilibrated by passing 5ml of
MACS buffer ofthe column 3x. After equilibration the column was placed into the
magnetic separator with a collection tube underneath and the labeled cells were pipetted
into the column. The cell suspension was allowed to run through the column and the
effiuent was collected as the negative fraction. The column was then washed 3 xs, each
time with 3ml ofMACS buffer, and again the efiluent was collected as the negative
fraction. After washing the LS+ column was removed from the magnetic separator, a new
collection tube was placed underneath the column, and 5ml ofMACS buffer was added to
the column. The CD l l e+ cells were collected by flushing out the column into the
collection tube with a plunger. A small fraction ofthe cells were then stained with a PE
labeled rat amouse CD 1 1c+ antibody (Pharmingen-San Diego, CA) and analyzed by
FACS. FACS analysis determined that the cell population was greater than 95% CD l lc+.

Cytotoxic T Cell /Chromium Release Assay
The CTL assay was performed as described earlier (57). In briefeffector cells
generated after a 5d in vitro expansion (with peptide or HSV) were analyzed for their
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ability to kill MHC matched antigen presenting targets. 2 x 1 06 target cells in 500µ1 RPMI
1640 were labeled with l00µCi of 5 lCr for 90min. After washing 104 labeled target cells
and serial dilutions of effector cells were incubated in 200µ1 of RPMI 1640 with 1 0% heat
inactivated FCS in 96 well V-bottom plates with 5 µg/ml of SSIEFRAL peptide. The
targets included syngeneic plus antigen, syngeneic cells with irrelevant antigen and
allogeneic cells with antigen. The plates were centrifuged at 500 g for 3 min and incubated
at 37°C and 5% CO2 for 4h. 1 00µ1 of the supernatant was collected to measure
radioactivity and specific cytotoxic activity was determined using the formula:

% Specific release = experimental release - spontaneous release x 100
total release - spontaneous release

Each assay was performed in triplicate and the spontaneous release was less than 25% of
the total release by detergent in all assays.
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Chapter III
Results
Production of recombinant mouse hsp70
Due to the fact that hsp70 purchased commercially is extremely expensive and
because very large quantities were needed recombinant mouse hsp70 was produced. The
production of this protein is discussed in the methods section. The E.coli, BL2 1 , was used
as a host for protein expression because they are Ion deficient, which prevents the
degradation of expressed protein due to lack of expression of certain proteases. These cells
also contain the lysogen DE3 that encodes T7 RNA polymerase. The presence of this
polymerase allows for the stringent control of RNA transcription from the lac operon that
controls the hsp70 gene in the pET expression vector. Upon induction screening of
transformants many were found to produce hsp70 under strict control of the lac operon.
The induction screen was run onto a gradient agarose gel (figure # 1 ). Following cell lysis
by high pressure, hsp70 was purified and isolated by ATP-affinity chromatography. In
order to optimize isolation and purification of the protein different forms of ATP agarose
were tested (A-6888, A-2767, and A-9267). After elution with 5mM ATP samples were
visualized on agarose gels (figures #2, #3 , and #4) and it was determined that A-2767 was
the preferred ATP agarose. Next a large scale preparation ofhsp70 was produced and
passed over A-2767, eluted, and run on an agarose gel (figure #5).
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In order to more highly purify the protein and assure that no contaminants were present,
the hsp70 preparation was passed over an ION-exchange column that contained Q
sepharose. The column was washed copiously with 1 1 OmM NaCl and subsequently eluted
with 200mM NaCl. After elution the protein was again run on an agarose gel and
visualized (figure #6). To confirm the presence ofhsp70 a western blot of the protein was
performed using a monoclonal antibody against hsp70 (data not shown). The western blot
confirmed the presence of hsp70. Samples of hsp70 were then quantified by
spectrophotometry, aliquotted, and stored at -80 °C until further use.

Trypsin Digest of Hsp70
Within all hsp70 that is hsp70 from different phyla and lineages there is a trypsin
sensitive site. Hsp70 exposed to trypsin digest results in the generation of two fragments;
one the ATP binding domain, and two the peptide binding domain. If prokaryotic hsp70 is
perfectly capable of binding and hydrolysis of ATP then during evolution and progression
of this protein into more advanced forms of life there would be no need to alter the NBD.
In fact, the previous point is upheld by sequencing data that indicates the NBD of all hsp70
is most similar with more dissimilarities arising in the proteins as the PBD is approached.
During testing of various hsp70 (e.coli, human, plant) from different phyla we found that
all were capable of inducing APC to produce inflammatory cytokines or they all function
as adjuvants (Discussed in a later section), but the different hsp70 were apparently not
capable of cross-priming antigens. This conclusion was drawn from data that indicated
immunization of mice with these hsp70 coupled to the immunodominant peptide,
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SSIEFRAL, fro'm HSV resulted in vastly different levels of protection to lethal challenge
with HSV. Due to the previous points; one-hsp70 is most similar at the NBD and most
different at the PBD, two-various hsp70 all functioned as potent adjuvants, three-not all
hsp70 were efficient in cross priming antigen as measured by viral challenges, our initial
hypothesis was that the NBD of hsp70 was responsible for the adjuvant properties of the
protein. To test this hypothesis we exposed mouse hsp70 to trypsin digest resulting in
cleavage of the protein and generation of two fragments, the NBD and the PBD (figure
#7). After digestion the cleaved products were passed over an affinity column containing
ATP agarose, which bound the NBD. Then the NBD was eluted with 5mM ATP and stored
at -80°C until use. The concentration of the NBD was calculated by its absorption of light
(li..=405nm) and found to be around 1 µg/µl.

Hsp70 Binds Dendritic Cells and Cross Presents Antigen
When this project was initiated it was unclear if hsp70 actually bound to DC. There
was much speculation that this was in fact the case prove was lacking. To address this
issue we pulsed a DC line DC2.4 with recombinant human hsp70 coupled to a hybrid
peptide that contained the SIINFEKL epitope and used fluorescent antibodies and confocal
microscopy to track the hsp70 and the antigen throughout the cell. The DC line was placed
on ice to prevent internalization of the hsp70, pulsed with hsp70, and stained with a
fluorescent anti-hsp70 antibody. After staining the cells were extensively washed and
consequently viewed under a confocal laser microscope. The images revealed bright
fluorescence on the surface of the cells indicative of bound hsp70 (figure #8).
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In a separate experiment DC2.4 was pulsed with hsp70 coupled to the hybrid peptide of
ova and left at 37°C for 2hr. After incubation the DC were stained with the antibody, 1 6
D. l 24, that binds to H-2b containing SIIFEKL. Subsequently the antibody was stained
with a FITC labeled rat anti-mouse antibody. This procedure revealed bright fluorescence
on the surface of the cells indicative of bound SllNFEKL (data not shown). Although we
failed to identify a specific receptor for hsp70 we did confirm that hsp70 binds to DC and
that the binding can lead to cross presentation of the hsp70 coupled antigen.

Adiuvant Properties of the NBD from Hsp70
After isolation of the NBD of hsp70 resulting from cleavage of the intact protein
with trypsin its adjuvant properties were tested. In order to determine the adjuvant
properties of the NBD, this portion of the protein, intact hsp70, and LPS at 1, 2, 5, and
lOµg quantities were used to pulse adherent cells for 24hr. Then using an ELISA based
assay 1NFa (figure #9) and IL-6 (figure #10) were measured and quantified. The results
are straight forward indicating that the adjuvant property of hsp70 is not contained within
the NBD. Although the data for the NBD is "negative" I feel comfortable that the data is
real since the results for both LPS and intact Hsp70 were positive and do correlate with
previous data.

63

2000

!

.e-

1 500

E1 1 µg,'ml
■ 2 µg,'ml
■ 5 µg,'ml
■ 1 0 ml

LL

z

� 1 000

500

NBD

LPS

HSP70

Adj uvant Properties of the Nucleotide Binding
Domain of Hsp70, Hsp70, and LPS
Figure #9

64

1600
1400
1200

<9 1000

.e

800
600

1 µg/ml
■ 2 µg/ml
■ 5 µg/ml
■ 1 0 µglml
EJ

400
200
0

LPS

NBD

HSP70

Adjuvant Properties of the Nucleotide Binding
Domain of Hsp70, Hsp70, and LPS
Figure #10

65

Adiuvant Properties of Hsp70 from Broad Phylogenetic
Lineages
Hsp70 from E. coli, DnaK, plant, CSS 1 and hsc70, and human, hsp70, were
analyzed for their adjuvant properties by pulsing narve adherent spleenocytes with the
various hsp70. The cells were pulsed with a l µg concentration ofvarious preparations
( 1 µg was chosen as the dose after preliminary dose response studies with human hsp70)
for 6 hours and stained for surface markers indicative ofmaturation status (CD80, CD86
and CD40). 106 splenocytes were stained with labeled anti-CD80, anti-CD86 and anti
CD40 after stimulation in vitro with the various hsp70. Unstimulated splenocytes were
stained with the same antibodies to serve as background for histogram overlay. The cells
were washed and analyzed using FACSCAN and Cell Quest software. While all ofthe hsps
were able to up regulate the surface expression (figure # 11) they differed in the intensity of
staining probably reflecting their dissimilarity in inducing maturation. A mixture ofall of
the hsps that was heat inactivated and added to the cell culture did not upregulate the
surface markers in the process ruling out the role for contaminating LPS in the
preparations contributing to upregulation. Alternatively, the adherent splenocytes were also
stimulated with l µg concentration ofvarious hsps for 24hr. The supernatant collected from
these cultures were analyzed for the presence ofpro-inflammatory cytokines IL-6, TNFq
and IL-12. Figures 12, 13, and 14 show the amount ofcytokine obtained as a consequent of
stimulation with various preparations. The supernatants collected from adherent splenocyte
cultures stimulated with various hsps were collected and analyzed by ELISA. The
concentrations ofeach cytokine were deduced from the standard curve obtained using
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recombinant cytokine. Supematants collected from unstimulated cultures served as
controls.Rh-hsp70 induced cytokines to the level seen with LPS stimulation. Dnak
produced three fourth the levels observed with LPS. CSSl was comparable to DnaK in
inducing TNFa and IL-12, but not IL-6. Hsc70 had very minimal activity, as observed
with activation markers. Heat inactivated preparations did not induce any pro
inflammatory cytokines ruling out LPS contamination. The results from these studies
indicate there are some minimal differences in the adjuvanticity and hence may not be the
contributing factor for the poor immunogenicity.

Hsp70, Hybrid Peptides and Immunity to HSV
Hsp70 is known to bind within areas if proteins or peptides that are hydrophobic in
nature. Therefore it is logical to assume that not all cognate class I epitopes will bind hsp70
with high affinity. In other words rules that govern the binding to class I antigens to MHC
molecules are different then rules directing the binding of potential antigens to hsp70. To
overcome the potential lack of affinity of antigens for hsp70 a peptide region with
increased affinity for the peptide binding domain of hsp70 was designed and placed in
front of either the immunodominant epitope from gB of HSV, SSIEFRAL, or from chicken
ovaalbumin, SIINFEKL. These hybrid peptides as well as their normal counterparts were
coupled to hsp70 and used to immunize mice so that a valid comparison could be made
between them. Initially, mice were immunized on day 0 and day 21 with varying doses of
hsp70 (0.1, 1, 2, 5 µg) coupled to a seventy fold molar excess of either the hybrid peptide or
the normal peptide and sacrificed on day 28. Splenocytes were tested for activation using
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tetramer analysis, intracellular interferon gamma staining, the chromium release assay, and
the ELISPOT assay. Due to the fact that hsp70 binds to the hybrid peptides with an
increased affinity in theory a greater amount of peptide should be able to achieve access
into the class I antigen presentation pathway and therefore more CDS+ T cells should
respond to the antigen. Our data do not support that claim. Using intracellular interferon
gamma staining (table #1), tetramer analysis (table #2), ELISPOT (table #3), and the CTL
assay (table #4) we found responses generated by the hybrid peptide and the normal
peptide were very comparable with the SSIEFRAL peptide coupled to hsp70 actually
performing slightly better then its hybrid equivalent in most assays. Many reasons could
account for these observations about the acute response generated by the hybrid peptides.
For example, such a large amount of peptide was used during immunization that the
increased affinity of the hybrid peptide was simply overcome by peptide concentration.
Another idea isthat the hybrid peptide binds hsp70 with such affinity that its does not
release the peptide into the cross-presenting cell efficiently.

Memory Response of Hsp70/Peptide and Hsp70/Hybrid Peptide
Due to very small differences in acute immunity generated by immunization with
either Hsp70/Peptide or Hsp70/Hybrid Peptide the memory response generated by either
vaccine was checked. C57BL/6 mice were immunized on day O and day 7 and 60 days
later sacrificed to determine the level of memory immunity produced. To check the
immune response assorted assays including tetramer analysis (table #5, appendix 1),
intracellular interferon gamma staining (table #6 appendix 1), ELISPOT (table #7), and the
chromium release assay (table#8) were employed.
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Table #1
% Primary CD8+ T Cells that were INFy positive
as determined by FACS analysis
Hsp70/
SSIEFRAL

Hsp70/
Javalin
SSIEFRAL

Hsp70

SSIEFRAL

Javalin
SSIEFRAL

0 . l µg

1%+/-0. 1 5

.23%+/-0.25

nt*

nt

nt

lµg

2.0%+/0-.2

1 .2%+/-0.5

nt

nt

nt

2µg

3 .3%+/-0.6

2.7%+/-0.4

nt

nt

nt

5 µg

6.5%+/-0.6

5 .6%+/- 1 . 1

0

cone.

0.3%+/-0.2
0
*nt - concentration not tested

Intracellular INFy staining was used to determine percent positive cells. Cells were cultured for 6hr in the
presence of Il-2, Brefeldin � and peptide. In between 500 and 1000 total live CDS+ T Cells were present
out of 20,000 cells analyzed as determined by staining with an anti-CD8a FITC antibody. Therefore 65
INFy/CD8a positive T cells were present in the groups immunized with 5 µg of Hsp70/SSIEFRAL and 56
were present in the 5 µg immunization with Hsp70/avalinSSIEFRAL.
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Table #2
% Primary CDS+ T Cells that are SSIEFRAL Tetramer
positive as determined by FACS analysis

Hsp70/
SSIEFRAL

Hsp70/
Javelin
SSIEFRAL

Hsp70

SSIEFRAL

Javelin
SSIEFRAL

0 . l µg

1 .7%+/-0.4

.0.8%+/-0.4

nt

nt

nt

l µg

2.9%+/-0.3

2.2%+/-0.7

nt

nt

nt

2 µg

4.5%+/-0.4

4.2%+/-0.4

nt

nt

nt

5 µg

7.6%+/-0.8

6.5%+/-0.6

0

0

l .2%+/-0.5

cone.

*nt - concentration not tested

Tetramer staining was used to determine percent positive cells. Cells were cultured for Sd in the presence of
Il-2 and peptide. In between 500 and 1 000 total live CDS+ T Cells were present out of 20,000 cells analyzed
as determined by staining with an anti-CD8cx FITC antibody. Therefore 76 Tetramer and CD8cx positive T
cells were present in the groups immunized with Sµg of Hsp70/SSIEFRAL and 65 were present in the Sµg
immuniz.ation with Hsp70/avalinSSIEFRAL.
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Table #3
INFy ELISPOT Data for Acute CDS+ T cells

Hsp70/SSIEFRAL

Hsp70/Javelin
SSIEFRAL

O.lµg - 10+/-4
l µg - 1 1+/-3
2µg - 21+/- 1 1
5µg - 54+/- 1 0
O.lµg - 4+/-2
lµg - 6+/- 1
2µg - 14+/-6
5µg - 26+/-8

*Vaccinia S SIEFRAL Immunized mice had 1 18 + cells
The chart above represents the average number of spots from per group. Groups were 3 mice immunized
with the corresponding amount of hsp70 coupled to the indicated antigen. Splenocytes from each mouse
were mixed with antigen and incubated for 48hr in ELISPOT plates per coated with anti-INFy antibody.
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Table #4
Killing by Primary CDS+ T Cells Primed with
Hsp70/SSIEFRAL or Hsp70 JavelinSSIEFRAL

Effector
To Target
Ratio

5 µg-Hsp70
SSIERFAL

5 µg-Hsp70
Javelin
SSIEFRAL

Vaccinia
SSIEFRAL

1 00 : 1

57%+/-6%

60%+/-4%

99%+/-0

50: 1

56%+/- 1 0%

57%+/- 1 %

96%+!-6%

25 : 1

45%+!-5%

48%+/-8%

93%+/-7%

12: 1

29%+/-9%

36%+/-8%

9 1 %+/-8%

6: 1

1 7%+/- 1 2%

30%+/- 1 0%

89%+/- 1 0%

3:1

1 2%+/-2%

27%+/-4%

7 1 %+/- 1 7%
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Table #5
% Memory CDS+ T Cells that are SSIEFRAL Tetramer positive
as determined by FACS analysis
Hsp70/
SSIEFRAL

Hsp70/
Javelin
SSIEFRAL

0. l µg

. 1 0%+/-.05

.40%+/-.20

nt*

nt

nt

l µg

.30%+/-. 1 7

1 .0%+/-.45

nt

nt

nt

2 µg

1 .2%+/-. 1 0

2.4%+/-.30

nt

nt

nt

5 µg

2.5%+/-.35

3 .8%+/-.75

0

0

0

cone.

Hsp70 SSIEFRAL

Javelin
SSIEFRAL

*nt - concentration not tested

Tetramer staining was used to determine percent positive cells. Cells were cultured for 5d in the presence of
11-2 and peptide. In between 200 and 500 total live CDS+ T Cells were present out of 20,000 cells analyzed
as determined by staining with an anti-CD8cx. FITC antibody. Therefore 12 Tetramer and CD8cx. positive T
cells were present in the groups immunized with 5 µg of Hsp70/SSIEFRAL and 20 were present in the 5µg
immunization with Hsp70/avalinSSIEFRAL.
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Table #6
% Memory CDS+ T Cells that were INFy positive
as determined by FACS analysis
Hsp70/
SSIEFRAL

Hsp70/
Javelin
SSIEFRAL

0. l µ g

0.0%+/-0

.20%+/-.20

nt*

nt

nt

l µg

.20%+/-. 1 0

.40%+/-.20

nt

nt

nt

2 µg

.50%+/-. 1 0

1 .3%+/-.30

nt

nt

nt

5 µg

1 .5%+/-.40

2. 1%+/-. 1 5

0

cone.

Hsp70 SSIEFRAL

Javelin
SSIEFRAL

0
0
*nt - concentration not tested

Intracellular INFy staining was used to determine percent positive cells. Cells were cultured for 6hr in the
presence of 11-2, Brefeldin A, and peptide. In between 200 and 500 total live CDS+ T Cells were present out
of 20,000 cells analyzed as determined by staining with an anti-CD8cx FITC antibody. Therefore 8
INFy/CDScx positive T cells were present in the groups immunized with Sµg of Hsp70/SSIEFRAL and 1 0
were present in the S µg immunization with Hsp70/avalinSSIEFRAL.
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Table #7
INFy ELISPOT Data for Memory CD8+ T cells

I

Hsp70/SSIEFRAL

O.l µg - 1 +/- 1
lµg - 3+/-2
2µg - 6+/-2
5µg - 12+/-5

Hsp70/Javelin
SSIEFRAL

O. lµg - 4+/-2
l µg - 4+/-4
2µg - 17+/-7
5µg - 23+/-5

*Number of spots for HSV Memory cells was 58
The chart above represents the average number of spots from per group. Groups were 3 mice immunized
with the corresponding amount of hsp70 coupled to the indicated antigen. Splenocytes from each mouse
were mixed with antigen and incubated for 48hr in ELISPOT plates per coated with anti-INFy antibody.
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Table #8
Killing by Memory CDS+ T Cells Primed with
Hsp70/SSIEFRAL or Hsp70 JavelinSSIEFRAL
Effector
70/SSIEFRAL 70/SSIEFRAL
To
Javelin
Javelin
Target 70/SSIEFRAL 70/SSIEFRAL
2 µg
2 µg
Ratio
5 µg
5 µg
1 00: 1

25%+/- 1 2%

5 1 %+/-8%

62%+/-9%

72%+/- 1 0%

50: 1

2 1 %+/- 14%

49%+/-3%

6 1 %+/- 1 1 %

64%+/-7%

25 : 1

20%+/-8%

44%+/- 1 0%

56%+/-2%

52%+/-9%

12: 1

6%+/- 1 0%

23%+/-7%

56%+/- 1 0%

5 1 %+/- 1 7%

6:1

3%+/-4%

1 7%+/-4%

42%+/- 1 %

35%+/- 12%

3:1

2%+/-5%

1 1 %+/-6%

30%+/-7%

26%+/-6%
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The data from each assay supported the finding that immunization with hybrid
peptide coupled to hsp70 was superior to immunization with hsp70 coupled to the normal
peptide. Interestingly, this conclusion is not in agreement with the acute data, which
implies both mixtures are equal in terms of immunity generated. This implies that there is a
difference in the quality not quantity of immunity produced during the primary phase so
that a larger number of CDS+ T cells are converted to the memory phenotype. There are
many potential reasons for this observation however no real concrete evidence. One reason
that I favor is peptide exposure to TCR. In other words hybrid peptides must be
internalized and processed by the proteasome prior to loading onto MHC molecules that
are transported to the surface to engage T cells therefore peptides generated by this route
are transported to the surface form inside the cell and remain there as long as the MHC
molecule. Normal peptides may simply displace other peptides within MHC already on the
surface of the cell, therefore the MHC molecule they are binding has already spent some
time on the surface and will be recycled more quickly then new MHC. The point being
hybrid peptides have a greater potential to engage T cells and also can engage those cells
for longer periods of time.

In Vitro Cross Priming Via Hybrid Peptides
During the evaluation of hybrid peptides coupled to hsp70 we stumbled into an
interesting observation. Initially the use of hybrid peptides was a simple way to cross
priming with hsp70 in vitro. In other words all of our in vitro systems respond to free
peptide and whenever hsp70 is coupled to any peptide such a huge excess of peptide is
used that even after copious washings small amount of free peptide remain that could cause
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a responder cell to react. It is believed that free peptide is able to displace other peptides
from the MHC I binding groove of APC and if those APC are present with T cell
hybridoma for example the hybridoma would respond to the peptide. Therefore we
believed that the peptide displacement phenomenon or excess peptide problem could be
overcome with hybrid peptides, which must be internalized to be presented, and our in
vitro studies of hsp70 could go forward. Therefore I designed an experiment to determine
the dose response curve of hsp70 and hybrid peptides in a system that used the T cell
hybridoma B3Z, which express a TCR that recognizes only SIIFEKL from ova, and
CD 1 1 c+ DC. Of course one of the controls in this experiment was to pulse the CD 1 1 c+ DC
with hybrid peptide alone without hsp70. To our astonishment a respectable response was
mounted as measured by the production of Il-2 from the T cell hybridoma B3Z, however
only CD 1 1 c+ DC were capable of cross presenting the hybrid peptides not adherent cells
(figure # 1 5). To follow up on this observation the optimal amount of peptide was
determined from a dose response curve (figure #16).
Since cross priming as a general rule results in presentation of antigens through the
class I pathway of antigen processing and presentation, which is proteasome and TAP
dependant, we sought to determine if the hybrid peptides were also exploiting this
pathway. To determine is cross presentation of hybrid peptides required their processing in
the proteasome CD 1 1 c+ DC were pretreated with the proteasome inhibitor lactacystin.
Pretreatment with lactacystin did in fact diminish the presentation of antigen on CD 1 1 c+
DC as determined by a decreased response from B3Z (Figure # 1 7). This decrease was
dependant upon the pretreatment concentration of lactacystin. Presentation was not
completely abolished arguing that the drug does not completely inhibit the proteasome and
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perhaps alternative pathways of processing could be employed by the hybrid peptides for
their processing (23 ).
Due to the fact that hybrid peptides have a high affinity for hsp70 and that hsp70 is
expressed on the surface of some cells it was our contention that surface bound hsp70 was
responsible for the binding and internalization of the hybrid peptides. To test this assertion
we used a panel of anti-hsp70 monoclonal antibodies to block surface hsp70, which in
theory should prevent the antigen from being presented. The various antibodies were raised
against different regions of human hsp70 and human hsc70. In this assay B3Z and CD l lc+
cells were mixed at a 1 : 1 ratio after the CD 1 1 c+ DC were pulsed with 100µg of either of
the hybrid peptides (figure # 18). The antibodies did partially inhibit B3Z from responding
implying that the DC were not presenting the antigen due to the antibodies preventing
surface hsp70 from binding and internalizing the hybrid peptides. The fact that
presentation of the hybrid peptide was only partial is not surprising and points to some
peptide being taken up by simple macropinocytosis or phagocytosis, processes that would
not be affected by anti-hsp70 antibodies.
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Chapter IV
Discussion
Hsp70 represents a potentially phenomenal vaccine component. Coupled to
immunodominant epitopes from any intracellular pathogen or tumor antigen hsp70 has
been shown to prime robust CDS+ CTL responses that are spawned in an environment full
of cytokines capable of augmenting the effectiveness of a CTL response. Normally
vaccines contain not only antigens required to prime specific immunity against a pathogen,
but also adjuvants that either contain bacterial toxins, which lead to an increase in non
specific tissue pathology, or compounds such as alum, which are only effective at priming
Th type 2 or humoral immunity. Due to the fact that the only adjuvant approved for use in
humans is alum and Th2 immune responses have limited effectiveness against intracellular
pathogens a new approach is needed in vaccine design. This is why hsp70 and other heat
shock proteins hold such promise, not only are they capable of delivering an exogenous
antigen into the endogenous pathway of antigen presentation they also prime a Th type 1
response, which involves cytokines such as INFy that dramatically increase the
effectiveness of cellular immunity.
Only very recently has our understanding of hsp70's role in immunity begun to be
elucidated. When this project was initiated cell types and receptors that interact with hsp70
were not known. Within the previous three years these various cells and receptors have
been discovered. Hsp70 has been shown to bind a variety of receptors (5-7, 9) on DC ( 14)
that leads to cross presentation and production of inflammatory cytokines from the
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engaging DC. Although we fell short of identifying the actual receptor for hsp70 we did
confirm that hsp70 binds to DC and that binding leads to cross presentation of the
chaperoned peptide.
In addition to cross presentation numerous reports indicate that hsp70 functions as
a powerful adjuvant (5, 6, 1 03). As previously stated no there is no adjuvant approved for
use in humans that can modulate immunity towards a Th I response. Therefore the need for
an adjuvant that can perform in this regard is obvious. Th l responses are critical for the
development of cellular immunity, which is strongly involved in containment and
clearance of intracellular pathogens like HSV or cancerous cells. When this project
initiated very little was known about the adjuvant properties of hsp70 therefore one of our
goals was to understand the adjuvant properties of this protein. In our studies we found
human hsp70 to be a strong adjuvant inducing high levels of ll-6, 11-1 2, and lNFa.
amounts that were comparable to those induced by LPS. Many recent reports claim declare
that hsp70 are capable of inducing the maturation of DC (10, 60, 93). Therefore we sought
to determine if hsp70 was capable of inducing the maturation of DC as measured by
upregulation of the costimulatory molecules CD40, CD80, and CD86. Our studies did
reveal that hsp70 when used to pulse DC was capable of up regulating the co stimulatory
molecules mentioned previously.
Due to the very high level of conservation found in hsp70 molecules from different
phyla one goal of this project was to determine if this conservation extended beyond amino
acid sequence and protein structure to immunological function. In order to access that
question hsp70 from e. coli and plant were compared to human hsp70 for their ability to
induce the production of inflammatory cytokines and for their ability to up-regulate co-
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stimulatory molecules. We found that there was little overall differences in this proteins,
except for the constitutive hsc70 from plant had very much reduced activity. The previous
point makes actually fits in line with our hypothesis that constitutive heat shock proteins
should not be able to function as immune regulators simply due to the idea that dysfunction
within the immune system such as autoimmunity could arise if responses were being
mounted against constitutively expressed protein.
Given that the various hsp70 tested had adjuvant capabilities we sought to
determine what portion of the protein was responsible for those abilities, the N-terminal
nucleotide binding region or the C-terminal peptide binding region. Recently in a paper
that describes Mthsp70 binding to CD40 on APC they also described the production and
testing of two plasmids that expressed either the NBD or PBD from Mthsp70 (108). The
authors reported that the PBD was actually responsible for binding to CD40 not the NBD.
Prior to this paper we attempted to make the same sort of evaluation, however we used
trypsin digest to generate the NBD instead of a plasmid. We sought to concentrate upon
the NBD due to its conserved nature compared to the PBD (70). In other words most of the
hsp70 from enormously different species react in a similar manner we subjected to an
adjuvant test and since each of these proteins is most related within the NBD our
hypothesis was that this was the region responsible for the adjuvant effect. To our
consternation we found that the NBD had no adjuvant properties. Due this finding the PBD
clearly must be tested. The issue with generating the PBD from trypsin digest is that this
portion of the protein is very hard to recover. The NBD binds ATP so affinity
chromatography is an easy reliable procedure to recover the NBD, however the PBD seems
to be much more trypsin liable and also cannot be recovered from any sort of affinity
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chromatography. Therefore a plasmid that contains this portion of the protein, size
exclusion chromatography, or ion-exchange chromatography needs to be employed to
isolate the PBD and test it for adjuvant properties.
The use of hsp70 and other hsp like gp96 coupled to immunodominant epitopes
from a variety of antigens have proven to be effective vaccines. These components can
either be coupled in vitro (26, 98, 99) or purified for cancerous tumors (43, 79, 94). This
form of vaccine has been proven to generate a very robust primary immune response,
however little has been reported about the memory response primed by this method. One
paper by Kumaraguru (57) does state that the durability or memory generated by this
means of vaccination was reduced when compared to alternative routes and less than
expected from such a robust primary response. In fact not only was the durability reduced
those CDS+ cell that did remain in the memory phase were shown to be functionally less
effective as measured by tetramer analysis and INFy. Due to the nature ofhsp70-peptide
vaccines having no class II antigens little if any CD4+ T cell help is recruited during the
primary immune response. Perhaps due to lack of help, which implies reduced cytokines
and reduced co-stimulation, CD8+ T cells are able to switch to a memory phenotype. In
order the issue imposed by this observation we employed the use of hybrid peptides, which
have a much higher affinity for hsp70 than their normal counterparts, in an attempt to
generate more protective immunity. In a variety of assays comparing memory immune
response from mice immunized with hsp70/peptide to hsp70/hybridpeptide we found that
the latter induced a quantitatively and qualitatively better response. It has been proposed
that the duration of TCR engagement with antigen and MHC can dictate the outcome for
the engaged T cell. In other words the T cell must engage the TCR for a certain period of
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time in order for all of the nessacary co-stimulatory molecules to be expressed on the
surface of the APC, if engagement falls below that time then proper ·stimulation is not
achieved. Since the hybrid peptides must be internalized and processed they are more
likely to presented on freshly exposed MI-IC while normal peptides can displace peptides
on partially out dated MHC all ready on the surface of the cell. In addition due to the
increased affinity hybrid peptides have for hsp70 a larger number of peptides can be cross
presented to APC, which gives more targets for scanning T cells to recognize and engage.
Therefore the increased immunity particularly in the memory phase of
hsp70/hybridpeptides could result from simply increased numbers of antigen on the APC
surface or it could arise from an increased duration of expression on the surface of the APC
or be a combination of both. This observation that hybrid peptides are a better source of
antigen in hsp70 based vaccines needs to be further evaluated by doing immunizations
followed by lethal viral challenges, to determine if this is a superior means-of vaccination.
Several substances have been shown to cross prime antigens or augment the cross
presentation of exogenous antigens (4, 30, 59, 87, 88, 105). Most of these substances
initiate the cross presentation of antigens by interaction with a Toll-like receptor, however
other receptors are involved. It seems that engagement of TLR leads to the production of
cytokines thus insuring that the delivered antigen is viewed by engaging T cells in the
proper environment to insure activation and not tolerance. Cross presentation of antigens
from substances that do not interact with TLR theoretically should lead to them tolerizing
T cells, such as the cross presentation of antigens from apoptotic cells. This brings up the
point about cross presentation of hybrid peptides that was observed with the B3Z/CD1 le+
system. In vitro using T cell hybridomas
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that have lower and different requirements for activation it appears the binding of hybrid
peptides to hsps on the surface of CD11c+ DC is able to activate T cells. In addition a
report by Germain (23) puts forth evidence that hybrid peptides used as a vaccine is able to
repeatedly prime low levels of CDS+ T cells, which supports our our unpublished
observations. Therefore binding hsps on the surface of cells, which leads to the cross
presentation of the antigen, might represent a viable means of antigen delivery. This
observation needs to followed up. It is not clear if the hybrid peptides are internalized to
the cell expressing the hsp on their surface or if it is released and taken up by another cell.
Also does this interaction cause cytokine production and if so which cytokines, or if not
how do CDS+ cells become activated by immunization with the hybrid peptide.
Many questions remain to be answered regarding hsp70 and its role in the immune
response. This field, although moving briskly along, has only been very active in the last
three years. It is known that there are at least eight mouse hsp70 genes and probably that
many or more in humans. Some of these proteins have very little differences that are seen
only in their signal sequence or peptide address, but others must play very different roles.
Are these roles divergent in terms of the immune response? Also is Hsc70 a player in
immunity. We made some preliminary observations that indicate it is not, however those
observations need to followed up. Finally why do hsp70/peptides vaccines fail to generate
an effective memory immune response? Does the lack of helper cell involvement preclude
the generation of potent memory or is there an all together different reason for this
observation. These questions and many more will surely be addressed in the very near
future.
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